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EXECUTIVE SUMMARY OF THE THESIS 
 
Caesarean section is the most widely performed major obstetric procedure. Even though regional block is often 
the anaesthesia of choice, general anaesthesia has its indications. Patients who deliver their babies by caesarean 
section under general anaesthesia deserve optimal pain management. Post-operative pain management is 
essentially multimodal, combining narcotics with non-steroidal anti-inflammatory and other interventions, including 
local anaesthetic infiltration in the wound or abdominal nerve blocks.  
 
Alleviating post-operative pain by the use of adjuvant local analgesia has been researched for several decades 
with conflicting reports. However, many obstetricians routinely infiltrate the wound with local anaesthetics, despite 
a lack of consensus on the technique or route of administration. To my knowledge, no reviews or metaanalysis of 
data have been done to support this practice.  
 
Most trials of local anaesthetics as an adjunct to pain relief have been carried out by using skin and subcutaneous 
wound infiltration. This technique of administration might have been responsible for producing conflicting results. 
Introducing a technique of anaesthetising all the layers of the anterior abdominal wound down to the peritoneum 
and comparing it to a placebo, may be one of a series of studies that can be undertaken to address the question 
of the efficacy of using local anaesthetics for post-caesarean section pain relief.  
 
The first part of this thesis is an experimental study design of a randomised clinical trial that was published in the 
official journal of the International Federation of Gynecology and Obstetrics (FIGO), the International journal of 
Obstetrics and Gynecology, in August 2008. This double-blind, placebo-controlled trial investigated the efficacy of 
routinely infiltrating the caesarean section wound and needle spraying, or infiltrating, the peritoneum with the local 
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anaesthetic agent, ropivacaine. The objective of the trial was to assess the effect of this intervention on post-
operative pain and the need for opioid use in the immediate post caesarean section period in women with planned 
surgical deliveries. The technique of infiltrating all layers of the abdominal wound was an innovation as compared 
to the subcutaneous and skin infiltration that has traditionally been carried out. The inclusion of the breached 
peritoneal surfaces was to address the deep pain of peritoneal injury that might occur from abdominal surgery. 
The results of this trial, using ropivacaine wound infiltration into all layers of the anterior abdominal wall, as 
adjuvant post-operative analgesia in elective caesarean sections for single uncomplicated pregnancies at term, 
showed a reduction in the need for narcotic analgesics and a reduction in the occurrence of severe post-operative 
pain in women undergoing general anaesthesia.  
 
There appears to be no recommended dose of local anaesthetics for a caesarean section wound infiltration and 
peritoneal application therefore, for the trial, we were concerned about exceeding the safety limits. The risk of 
serum toxicity from peritoneal application of the local anaesthetic might be high as the absorption of drugs and 
fluids through the peritoneum is generally optimal. Hence, for the clinical trial, we adopted the dose used for 
brachial plexus block. If this baseline dose produced a serum concentration that was within the safety margin 
(less than toxic concentration); a dose finding trial of lesser concentration could be embarked upon. This 
motivated the need for the serum concentration study published in the International journal of Obstetrics and 
Gynaecology in January 2009. Using high performance liquid chromatography in 71 serum samples at different 
time intervals, the maximum concentration of ropivacaine using a dosage of 225mg by infiltration through all 
layers of the anterior abdominal wall incision, including the peritoneum at caesarean section was 1553 (SD 793) 
ug/L. This falls within the safety range in humans, and below levels reached following brachial plexus block.  
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The last part of the thesis combines all suitable randomised trials, including the clinical trial described above, in a 
systematic review, to advise health care providers on the role of adjuvant local anaesthetic infiltration in 
caesarean section pain relief. The decision to include the author‘s trial was made by an independent Cochrane 
reviewer based on strictly objective criteria.  
 
The systematic review of the effects of this health care intervention of local anaesthetic infiltration in caesarean 
section wounds was edited by the Pregnancy and Childbirth group of the Cochrane collaboration, Liverpool, 
United Kingdom. The review addresses a clearly defined question and explains how studies for the review were 
located, selected and excluded. It gives details of the search strategy used, explains how data were collected 
from studies, how missing data were handled and how study quality was assessed. In twenty trials involving 1150 
patients, it concludes that local anaesthetic wound infiltration and abdominal nerve blocks as adjuncts to regional 
and general anaesthesia, were of benefit in caesarean section by reducing opioid consumption. Non-steroidal 
anti-inflammatory drugs as an adjuvant conferred additional pain relief.  
 
The importance and relevance of the systematic review, which was published in two peer review journals, can be 
inferred by the interest which it has generated in the press worldwide. This may provide indirect evidence of its 
potential to change clinical practice. A PhD thesis, inter alia, needs to contribute to the advancement of 
knowledge. The potential of the systematic review to achieve this was recognised by Faculty 1000,  ‗a 
revolutionary literature awareness service that identifies and evaluates the most important articles published in 
Medicine based on the recommendations of a Faculty of over 2000 peer-nominated leading researchers and 
clinicians‘, by way of an award.  
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Pain management, in the modern medical practice, is a sub-specialty that falls within the domain of anaesthetists. 
A thesis on the subject might appear not to be a primary responsibility of an obstetrician. However, after the 
anaesthetist has completed the broader duty of advising on post caesarean section pain management, it is the 
obstetrician who is faced with further augmenting or modifying pain relief prescribed by the anaesthetists. In 
addition, if wound infiltration is to be employed, the obstetrician who performs the procedure is better placed to 
administer the intervention intra-operatively. Based on this premise, it is appropriate that an obstetrician 
conducted studies on local anaesthetic as an adjunct to caesarean section pain relief. 
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CHAPTER ONE 
REVIEW OF THE LITERATURE 
 
Synopsis 
The discovery, extraction and clinical applications of local anaesthetics in Europe, in the 19th century, brought 
about a quest for wider clinical applications in the decades that followed. Local anaesthetics wound infiltration 
appeared to be reasonable but in clinical studies, results were variable. In this chapter, I summarise the anatomy 
of the anterior abdominal wall, where the local anaesthetics will be applied. In addition, I discuss the 
pathophysiology of pain and pharmacology of local anaesthetics, and review the different modalities of 
management of post-caesarean section pain. Regional anaesthesia is the anaesthesia of choice for performing 
caesarean section but indications for general anaesthesia remain; these indications are discussed. The method of 
local anaesthetics assays using chromatography is discussed.  
 
Child birth is a profoundly emotional experience for the mother and her family. This is a time when a new 
individual is added to the family, a time that is filled with age old rituals and modern routines. Ideally, this period 
should be as pain-free as possible to enable the mother to perform her immediate maternal and social 
responsibilities. Caesarean section delivery may predispose to negative emotions, especially if social support 1 
and immediate post-operative pain management are sub-optimal. 
 
Caesarean section is widely performed, and different rates for this procedure are quoted all over the world. What 
is certain is that the rates are ever increasing. The World Health Organisation recommends an optimum rate of 5-
15% to ensure the best outcome for mother and neonate.2 In the United Kingdom, in 2001, 21% of all deliveries 
was by caesarean section.3 In the private health sector in South Africa, a much higher figure of 57% was noted in 
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a study published in 2002 4 and 60.4% in another study published in 2009.5 A major South African medical aid 
company reported a rate of 63% in a 2004 audit 6 and a study comparing the number of caesarean sections in 
South African  government-funded institutions to private hospitals, found a 50% increase in the latter. 7  
 
Whilst regional anaesthesia (spinal and/or epidural block) is usually performed for caesarean section because it is 
safer and results in less morbidity, general anaesthesia is sometimes indicated. Approximately 16% of caesarean 
sections in the UK are performed under general anaesthesia and failure of regional anaesthesia accounts for 10% 
of these cases.8 General anaesthesia is indicated if the patient declines a regional approach, if there is any 
clinical contraindication to neuraxial blockade e.g. coagulopathy, or when time is of immense necessity e.g. acute 
severe fatal compromise.8 Lack of resources, manpower, skill and to a lesser extent, materials to insert a regional 
anaesthetic, are further reasons why general anaesthesia may be administered. Low resource centres may 
perform more caesarean sections under general anaesthesia: a report from a sub-Saharan University Teaching 
Hospital showed that all caesarean sections (8.4% of all deliveries in the centre) between January 2006 and April 
2007 were performed under general anaesthesia.9   
 
The management of post-operative pain for caesarean sections performed under general anaesthesia usually 
involves the use of opioids and non-steroidal anti-inflammatory drugs (NSAIDS). Such pain relief is often 
inadequate, especially within the first few hours following surgery. 
 
Several studies on local anaesthetics for post-operative pain in general surgery have produced varying reports, 
ranging from being beneficial, 10, 11 to no benefit 12, 13. Despite these conflicting reports, without the evidence and 
guidance from systematic reviews, the practice of local anaesthetic wound infiltration has slowly crept into the 
surgical routines of obstetricians. It is imperative to test medical practices by well conducted trials, where possible 
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and where there are doubts, before accepting such practices as the norm. 14 It is for this reason that I was 
motivated to understand and explore the use of local anaesthesia as an adjunct to post caesarean section pain 
relief. 
 
1.1. The surgical anatomy of the anterior abdominal wall 
 
Knowledge of the anterior abdominal wall anatomy is important to obstetricians and surgeons in general, before 
entering the abdominal cavity. This is important in discerning the locations of major blood vessels, nerves and the 
visceral organs, thereby avoiding injuries to tissues. For the anaesthetists and surgeons who perform abdominal 
nerve blocks, a sound knowledge of the anterior abdominal wall anatomy enables identification of the sites to be 
used and circumvents damage to the nerves and inadvertent intravascular injection of anaesthetic drugs. 
 
1.1. 1. The muscles and aponeurosis of the anterior abdominal wall 
The hexagonal appearance of the outline of the anterior abdominal wall has boundaries of which the superior 
margin is termed the costal margin. The lateral boundary is the imaginary mid-axillary lines between the lateral 
part of the costal margin and the iliac crest. The inferior border on either side runs from the iliac crest, inguinal 
ligament, pubic crest and pubic symphysis. During laparotomy, the layers of the anterior abdominal wall, which 
are encountered from the skin inwards into the peritoneum, include the superficial fascia of Camper‘s and 
Scarpa‘s, a musculo-aponeurotic layer, transversalis fascia, a pre-peritoneal adipose layer and the parietal 
peritoneum.15 
 
The absence of deep tendons in the muscles of the anterior abdominal wall facilitates ease of abdominal wall 
distension, for example, during breathing movements and in pregnancy. The functions of abdominal muscles 
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include flexing the trunk, as accessory muscles of respiration, defecation and protection of intra-abdominal organs 
against trauma. 16 
 
To aid mobility and distension of the abdominal wall, the skin over the anterior abdomen is more mobile than the 
skin covering the back. Skin creases run fairly horizontally above the umbilicus and infero-medially below and 
more distinct suprapubically. Transverse incisions made along the skin crease tend to heal better compared to 
incisions that are made perpendicular to the creases.  Beneath the skin is a fascia of adipose tissue followed by 
the fibro-elastic layer (Scarpa‘s fascia). Beneath this fascia is a musculo-aponeurotic layer which is formed by the 
rectus abdominis muscles that come from either sides of the abdomen meeting at the midline. This layer is 
contained within the rectus sheath that is formed by division in the aponeurosis of the internal oblique muscle. 
Posteriorly, it is reinforced by the aponeurosis of the transversus abdominis and anteriorly by that of the external 
oblique. Anteriorly, the sheath is adherent to the rectus muscle whilst posteriorly, it is loose. The lateral muscles 
fill the space between the rectus and the lumbar muscles and between the costal margin and the iliac crest. The 
external oblique muscle arises by fleshy digitations from the outer aspect of each of the lower eight ribs near their 
costochondral junctions. The fibres of the external oblique pass downwards and medially, those of internal oblique 
run upwards and medially and those of transverses abdominis run transversely. Below this line, the muscles 
become aponeurotic and their fibres pass downwards and medially in the formation of the inguinal canal. The 
inguinal ligament is the rolled lower border of the aponeurosis of the external oblique.16   The linea alba, which 
runs from the xiphoid process above to the pubic symphysis below, is a midline inter-digitation of the aponeurosis 
of the external oblique, internal oblique and transversus abdominis of one side with the other side. It is more 
pronounced and wider above the umbilicus than below. 15 
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1.1.2. The lymphatic drainage 
The lymphatic drainage of the lower abdominal wall consists of between 10 and 20 superficial interconnecting 
inguinal lymph nodes. These are located in the region of the inguinal ligament. Anastomoses are found between 
the lymph vessels of the right and left sides of the abdomen.17 
 
1.1.3. Blood supply to the anterior abdominal wall and the peritoneum 
The anterior abdominal wall has a rich blood supply. The posterior rectus sheath contains the inferior epigastric 
vessels which anastomose with the superior epigastric artery and vein, the terminal branches of the internal 
thoracic vessels. These vessels may be damaged during a rectus block, insertion of lateral trocar when 
performing a laparoscopy, or when inserting an intra-abdominal drain.16  They may also be damaged when 
performing a transverse lower abdominal wall incision for caesarean section. The visceral peritoneum is supplied 
by the vessels from adjacent organs while the parietal peritoneum is supplied by branches from musculo-phrenic 
arteries, lumbar arteries, inferior epigastric and deep circumflex iliac vessels. 
 
1.1.4. Nerve supply of the anterior abdominal wall and the peritoneum  
The subcostal nerves (anterior primary rami of T7 to L10) lie between the internal oblique and transversus 
abdominis and supply the anterior abdominal wall. Each subcoastal nerve has a lateral cutaneous branch that 
goes through the rectus and innervates the overlying dermatome. The eleventh intercostal and subcostal nerve 
supply the dermatome below the umbilicus; the tenth supply the skin around the umbilicus while the seventh 
supplies the skin around the epigastrium (Figure 1.1). The iliohypogastric and ilioinguinal nerves (L1) supply the 
skin immediately above the inguinal ligament and pubic symphysis.15, 16These two nerves are relevant in 
transverse lower abdominal incisions and midline sub-umbilical incisions usually used for performing caesarean 
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sections. It is relevant to both wound infiltration analgesia and direct blockage of the ilioinguinal and 
iliohypogastric nerves. 
 
The peritoneum is a layer of mesothelium which envelopes the abdominal and pelvic organs. It consists of the 
pain sensitive parietal peritoneum and stretch sensitive visceral peritoneum. The visceral peritoneum in the lower 
pelvis is supplied by the sympathetic nerves of underlying visceral. Apart from sensitivity to stretch, the receptors 
are also sensitive to ischemia and spasm of smooth muscles. The parietal peritoneum overlying the diaphragm is 
supplied by the innervations from C3-C5 hence referred pain to the shoulder dermatomes when irritated. The 
supply over the parietal peritoneum generally is from the lower thoracic to the first lumbar nerve roots. 18 
 
 
 
The technique of ilioinguinal or iliohypogastric and the twelfth thoracic (T12) nerve block requires knowledge of its 
surface anatomy. The land mark for these nerves in surface marking is about 3cm inferior and 3cm medial to the 
anterior superior iliac spine. T12 and iliohypogastric nerves run between the internal oblique and the external 
Fig 1.1. Dermatomes of the anterior abdominal wall 19 
22 
 
oblique muscles. The ilioinguinal nerves initially run between the transversus abdominis and the internal oblique 
muscles. Inferiorly thereafter, it pierces the internal oblique muscles around the region medial to the anterior 
superior iliac spine. It runs antero-medially to supply the muscles and skin in the inguinal and the suprapubic 
regions.20 These are the areas of incision involved in performing a Pfannenstiel or modified Pfannenstiel 
caesarean section.  
 
The technique of ilioinguinal and iliohypogastric nerve blocks 
Several studies involving anterior abdominal nerve blocks as an adjunct to post caesarean section pain relief 
have been done. 21 The technique of ilioinguinal and iliohypogastric nerve blocks involves identification of the 
anterior superior iliac spine. Approximately one finger breadth below and lateral will identify the point of insertion 
of a 3.5 cm long, 22 gauge needle placed perpendicular to the skin. On piercing the external oblique muscle, a 
―click‖ may be felt where the first volume of local anaesthetic is injected to block the iliohypogastric nerve. A 
further, slightly deeper, advancement of the needle in the same plane gives the second ―click feeling‖, that 
indicates the piercing of the internal oblique to block the ilioinguinal nerve. With the needle in situ, and redirecting 
it medially and laterally, volumes of local anaesthesia are infiltrated around the lateral cutaneous branches of the 
subcostal nerves. The use of an ultrasound guide to identify the nerves, improves the efficacy of local 
anaesthesia, compared to the use of anatomical land marks. Where resources are available, training with sono-
anatomy prevents inadvertent nerve and visceral injuries. 20 
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1.2.  The history of caesarean section 
Caesareans have been part of human medical history, both in the cultures of the western and the non-western 
worlds. This surgical procedure, over the centuries, has been the source myths, legends and heroes, in written 
and oral history. A study on post-caesarean section pain management would not be complete without a brief on 
how the procedure evolved into the modern procedure of the 21st century.   
Deliveries by caesarean section, in the early ages, were essentially heroic and were performed to save the babies 
that would have otherwise perished with the mothers. The term ‗caesarean section‘ was derived from the Latin 
word ‗caedo‘ (to cut). It is unsure when the procedure was first performed. Legend has it that the Roman emperor, 
Julius Caesar, was born by a caesarean section but this was refuted in many quarters, because it was noted in 
history that Julius Caeser‘s mother lived to witness the golden reign of her son. It would have been an impossible 
feat to survive the complications of such surgery at that point in human medical history.  
An emperor of Bindusara, India, is said to have been born by caesarean section during 320 BC, as was an Iranian 
icon, Rostam, in a book written in 1000 AD.  In 1204, Saint Raymund Nonnatus was born by caesarean section 
(‗nonnatus‘ means not born) as was King Robert II of Scotland in 1316, however neither of their mothers 
survived.22, 23 
An animal husbandry practitioner, Jacob Nufer from Switzerland, was the first person recorded to perform a 
caesarean section during which the mother survived. In the United States, the first recorded caesarean section 
was in 1794. In Africa, caesarean section was first recorded in Uganda in 1879, performed by local African 
traditional healers, although in other regions it might have been performed much earlier.  22, 23  
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Although survival was possible, it was not the norm, and the mortality rate in the United Kingdom for caesarean 
section in 1865 was 85%. In Paris, France, between the periods 1787 to 1876, there was no record of any 
maternal survivors.  With improvement in medical practice, surgical techniques and the advent of anaesthesia in 
the nineteenth century, the mortality rate started declining. In 1882, Max Sanger introduced sutures in the form of 
silver wires to close the uterine incision. Marion Sims had earlier invented the wires to close vesico-vaginal 
fistulas.  
With improved survival in the late nineteenth century, surgical attention was focused on the technique of 
performing caesarean sections to further reduce morbidity and mortality by preventing uterine rupture, reduce 
blood loss and sepsis. This was the reason for advocating lower segment caesarean section between 1880 and 
1925 – a technique started by a Briton, Munro Kerr, and which was quickly taken up by the Americans. A further 
major reduction in mortality occurred after the discovery of penicillin by Alexander Fleming in 1928. With 
increasing safety of caesarean sections, came an increase in the rate of performing the procedure. Many more 
hospitals were built, medical knowledge improved and surgery became safer. This led to a further increase in 
caesarean sections, such that the high rates seen today are a source of concern in modern obstetrics. 22, 23 
 
1.3. Surgical incisions for performing caesarean section 
The abdominal cavity may be explored surgically by vertical, transverse or oblique abdominal incisions. 
Traditionally, midline incisions were used for performing caesarean sections and, as in other surgical conditions, 
required a laparotomy. These later evolved to transverse lower abdominal incisions like the Pfannenstiel incision. 
Other transverse incisions used in the surgery of the anterior abdominal wall are the Joel-Cohen (a modified 
Pfannenstiel incision), Maylard transverse muscle cutting incision and the Kocher‘s subcostal incision. 24  
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1.3.1. The midline incision  
The midline incision has several advantages over other types of abdominal incisions including minimal injury to 
blood vessels, nerves and muscles, quick and wider access to the abdominal cavity 24 and the possibility of 
extension to the supra-umbilical midline of the epigastrium. 25 However, midline incisions do not give good 
cosmetic results and have a higher predisposition to wound breakdown and incisional hernias. Performing a 
caesarean section under local anaesthesia is more effective with vertical incisions. 26 A modification of the midline 
incision is the paramedian incision which may be easily extended above the umbilicus for improved intra 
abdominal exposure. The scar is not appealing but it is stronger, with less chance of herniation. 27  
 
1.3.2. The Pfannenstiel incision 
The Pfannenstiel incision which was described in the beginning of the 20th century by Pfannenstiel, and with its 
various modifications over the decades, is used frequently by gynaecologists for access to the pelvic organs and 
for caesarean section.28 The skin incision, which is made in a skin crease about five centimetres (cm) above the 
symphysis pubis, is approximately 12 cm long. The incision is carried deeper into the abdominal wall through fat 
and fascia until the rectus sheath is reached. The latter is then divided across the length of the incision exposing 
the anterior rectus muscle. The aponeurosis is separated towards the umbilicus superiorly and almost towards the 
pubis inferiorly. The rectus muscles are thereafter separated laterally to expose the underlying parietal 
peritoneum which is opened vertically and retracted to expose the lower segment of the uterus. Pfannenstiel 
incisions heal quite well with good apposition and cosmetics. 29 
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1.3.3. Maylard, Cherney and Mouchel incisions 
The Maylard incision is a slight modification of the Pfannenstiel incision where better exposure is necessary to 
deliver the baby. The rectus abdominis muscle is sharply dissected or cut. There is, however, more blood loss 
and more damage to muscular tissues.  29 Cherney‘s incision is also a muscle cutting incision like Maylard, but it 
involves dissecting the rectus attachment to the pubic symphysis. 30 A Maylard–type incision by Mouchel was 
described in 1981. The skin incision is at the line of pubic hair, which is therefore lower than the standard Maylard 
incision; it involves cutting the muscles above the opening of the inguinal rings.31 
 
1.3.4. The Pelosi incision 
A transverse suprapubic incision is cut and the subcutaneous and fat layer, deepened to the rectus fascia with 
electrocautery. The latter is sharply incised and the rectus muscle bluntly separated. The peritoneum is often 
entered bluntly, and the abdominal wound stretched to expose the uterus. The bladder is not reflected from the 
uterus and the baby is delivered. The placenta is allowed to separate spontaneously, and the uterus is closed in 
one layer. The advantage of a Pelosi‘s incision is the speed of surgery and reduced blood loss. 32 
 
1.3.5. The Joel-Cohen based incisions and techniques 
These methods of performing a caesarean section are modifications to the Pfannenstiel incision technique. The 
skin incision is made about 3cm above a line joining the anterior superior iliac spines. The fat and the 
subcutaneous tissues are slightly opened at the centre - mostly with blunt dissection. The rectus is reached, 
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which is slightly opened sharply at the centre. The fingers are used to push the incision edges laterally for 
exposure. The peritoneum is entered often with blunt pushing and stretching and the uterus exposed.  The uterus 
is closed in one layer. With non closure of the peritoneum, and avoidance of sharp dissection in most of the steps 
described above, the technique was popularised in the Misgav-Ladach Hospital in Israel. This method was named 
after the institution. The operating time was short, blood loss minimal, and with less post-operative pain. 33.  
A Cochrane review 32 compared the Joel Cohen type of caesarean section to the traditional Pfannenstiel 
caesarean section and found reduced blood loss and reduced operating time in the former. In addition, there was 
reduced time to delivery of baby, less post-operative pyrexia, fewer analgesic consumption and shortened period 
of post-operative pain. The conclusion of this review was that the Joel Cohen based caesarean section was 
advantageous in reducing postoperative morbidity and reducing the cost associated with performing caesarean 
delivery. 32, 33 
 
Table 1.1, adapted from the WHO Reproductive Health Library, 29 describes the various techniques of performing 
caesarean section. After delivery of the baby, various approaches and methods of closure of the abdominal 
wound incision are described. This is summarised in the WHO Reproductive Health Library as depicted in Table 
1.2. 
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Table 1.1. Types of incision of tissues in different techniques of caesarean section (Adapted from the 
Reproductive health Library). 29 
Technique 
 
Skin Subcutaneous 
layer 
Rectus sheath Rectus 
muscle 
Peritoneum Uterus 
Pfannenstiel Transverse 
Sharp 
Not specified Transverse 
Sharp dissection 
from muscles 
Not specified Longitudinal 
sharp 
Transverse  
Lower segment 
Pelosi-type Transverse  
Sharp 
Electrocautery 
Transverse 
Electrocautery 
Transverse 
Blunt 
separation 
Blunt Transverse  
Lower segment 
Blunt or sharp 
Joel-Cohen Transverse  
Sharp     
Higher than 
Pfannenstiel 
Incision in 
midline, then 
blunt along with 
rectus sheath 
Incision in midline, 
then blunt along 
with subcutaneous 
layer 
Blunt 
separation 
Blunt Transverse  
Lower segment 
Blunt 
Misgav-
Ladach 
Transverse 
Sharp     
Higher than 
Pfannenstiel 
Not specified Blind thrusting 
movement of the 
open scissor-tips 
Not specified Blunt Transverse  
Lower segment    
Blunt 
Modified 
Misgav-
Ladach 
Transverse  
Sharp    
Higher than 
Pfannenstiel or 
opened at the 
level of the 
Pfannenstiel 
incision for 
cosmetic 
reasons 
Not specified Blind thrusting 
movement of the 
open scissor-tip 
Not specified Visceral 
peritoneum 
not opened 
Transverse  
Lower segment   
Blunt 
Traditional 
vertical 
Vertical   
Sharp 
Vertical   Sharp Vertical   Sharp Blunt or 
sharp 
separation 
Longitudinal 
sharp  
Transverse  
Lower segment  
 Blunt or sharp 
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Table.1.2: Types of closure of tissues in different techniques of caesarean section (From the 
Reproductive Health Library). 29 
Technique 
 
Uterus Peritoneum Rectus 
sheath 
Subcutaneous 
layer 
Skin Other 
Pfannenstiel Two layers 
Continuous 
Both layers 
closed   
Continuous 
sutures 
Continuous or 
interrupted 
sutures 
Not specified Interrupted or 
continuous  
 
Pelosi-type Single layer 
Continuous 
Not closed Continuous 
sutures 
Interrupted 
sutures if 
needed 
Staples Bladder not 
reflected 
inferiorly 
Spontaneous 
delivery of the 
placenta 
Joel-Cohen Interrupted Not closed Continuous 
sutures 
Not specified Not specified Bladder 
reflected 
Misgav-Ladach Single layer 
Continuous 
Not closed Continuous 
sutures 
Not specified Two or three 
mattress 
sutures 
Placenta 
removed 
manually  
Uterus 
exteriorized for 
closure 
Modified Misgav-
Ladach 
Single-layer non-
locking 
continuous 
sutures, or closed 
with two non-
locked sutures 
layers 
Not closed Continuous 
sutures 
Not specified Subcutaneous 
suture or 
various skin 
closure 
methods 
 
Traditional 
vertical 
Single layer or 
two layers 
Continuous or 
interrupted 
Both layers 
closed  
Continuous 
sutures 
Continuous or 
interrupted 
sutures 
Interrupted 
sutures 
Interrupted or 
continuous 
suture 
Bladder 
reflected 
inferiorly 
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1.4. The pathophysiology of post-operative pain 
Pain is a sensory-emotional experience.34 It originates from external noxious stimuli from the environment that 
cause a localised sensation in a part of the body, to which the individual‘s response will be to terminate or escape 
the source of the stimulus. Acute post-operative pain and hyperalgesia is associated with peripheral and central 
sensitisations.35 In peripheral sensitisation, the peripheral, small diameter, non-myelinated, afferent neurons lower 
their response threshold, increase the magnitude of response and also increase spontaneous activity .36 The 
neurons, A delta and C fibres, are stimulated by inflammatory mediators like hydrogen ions, noradrenaline, 
bradykinin, potassium ions, histamine, prostaglandins, purines, cytokines, leukotrines, nerve growth factors and 
neuropeptides. 37 After peripheral sensitisation, impulses are sent to the central nervous system. This is central 
sensitisation, when the transformed pain signals are increased in intensity.38 Central sensitisation occurs when 
the dorsal horn neurons in the central nervous systems are stimulated by the insult to tissues. Action potentials 
are generated by activation of calcium channels in the cell membranes by specific proteins that respond to 
various stimuli, such as changes in temperature, pressure or acidity. Changes in pH are found during 
inflammation and ischemia of uterine and skeletal muscles. The proteins that are involved in this acidic condition 
are mediated by the Acid Sensing Ion Channels (ASICs). 39 
 
1.4.1. The physiological response of the body to painful stimuli 
The body responds to pain physiologically by involving most systems of the body.40 The endocrine and metabolic 
response to surgical trauma starts intra-operatively, by activation of a sympathetic nervous mechanism that leads 
to, amongst other things, hyperglycaemia, lipolysis and protein degradation. This stress response shows clinically 
31 
 
as tachycardia, hypertension, and renal function impairment. Epidural analgesia with local anaesthesia obviates 
this response.40  
The respiratory response is due to many factors. Uncontrolled pain impairs the sub-phrenic nerve and 
diaphragmatic activities, as well as voluntarily inhibiting breathing activity. There is less diaphragmatic descent 
and reduced lung volumes secondary to the decrease of output from phrenic motor neurons.41 The decrease in 
pulmonary functions may be made worse by the administration of opioids. In addition, anaesthetic agents impair 
central control of breathing and depress activities of the respiratory muscles. This results in the loss of 
coordination of respiratory muscle activity, thereby leading to sub-optimal lung functions.  
 Ileus is a common occurrence post surgery caused by a combination of surgical stress and pain, mediated by 
sympathetic hyperactivity. The reduced gastrointestinal motility is a result of many factors. Local inflammation, 
spinal, supraspinal and adrenergic response can initiate inhibition of neurogenic pathway.41 Systemic or epidural 
opioids can aggravate an ileus. 
The cardiovascular system responds with an increase in catecholamine and sympathetic activity causing 
tachycardia, hypertension and generalised vasoconstriction. Of concern is the sympathetic activities on the 
cardiac muscles that can increase oxygen demand, and in previously cardiac compromised individuals like the 
elderly, may lead to angina dysrhythmias with the possibility of generating areas of cardiac ischemia. The 
sympathetic stimulation may generate hyper-viscosity which may lead to coronary thrombosis, in turn translating 
into further myocardial ischaemia.41  
Acute pain may also result in impairment of cognition. The mechanism post-operative cognitive dysfunction is 
postulated to be due to dysregulation of central neurotransmitters in the cerebrum. The effect is further mediated 
by factors such as type of surgery, intra-operative anaesthetic or analgesic medications, post-operative analgesia 
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and patient‘s age. Imbalance in the centrally acting neurotransmitters, such as cytokines, serotonin and 
acetylcholine, may play a major role. Surgeries involving the heart tend to produce micro-embolism that may 
cause cerebral vascular microthrombi and decrease cerebral perfusion - causing delirium and impaired cognitive 
function.40, 41 
The immune system, both cellular and humoral, is suppressed partly due to the release of glucocorticoids and 
pro-inflammatory tumour necrosis factor, interleukins and cytokines.40 Cytokines released intraperitoneally may 
lead to immunosuppression which may be a factor in occurrence of peritonitis in open laparotomy. Laparoscopic 
surgery that involves less tissue manipulations will therefore have fewer complications. 
 Another response to post surgical acute pain is initiation of hypercoagulability. This is mediated by stasis, 
vascular injury and the formation of thrombus and is associated with an increase in tissue factor and plasminogen 
activator. The process is maintained or propagated with clot formation and stabilisation.41  
For effective post-surgical analgesia, interventions at the levels of peripheral sensitisation, mediators and central 
sensitisation requires a multimodal approach to pain relief. In addition to local anaesthetics, other interventions 
that may be used as part of a multimodal approach include the following: 
1. Opioids: Post-operative pain management is centred on opioids, although side-effects are common. 
Administration is best via infusion pump as patient-controlled analgesia. 
2. Non-opioid analgesics: These act in synergy with opioids and have fewer side-effects. Examples are cyclo-
oxygenase inhibitors, alpha-2 agonists, nitric oxide and N methyl–aspartate. 
3. Non-steroidal anti-inflammatory drugs: NSAIDs inhibit prostaglandin synthesis. The platelets and 
gastrointestinal side effects are affected by cylooxygenase isoenzymes (COX-1). 
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4. Other analgesics: These includes clonidine, an alpha-2 agonist, nitric oxide inhibitors, acetaminophen and 
ketamine (N-methyl D aspartate blocker-NMDA). 40 
1.4.2. Chronic pain  
There may be a higher incidence of chronic pain in sub-optimally managed acute pain, in procedures where major 
nerves were severed, as in thoracotomy and amputation, and in patients who experienced uncontrolled pre-
operative pain. Chronic pain may be attributable to central desensitisation and NMDA sensitisation. Drugs that 
have NMDA antagonist properties like ketamine and methadone may be useful in preventing chronic pain, 
however clinical studies have shown conflicting results.42 
 
1.5. Local anaesthetics 
 
1.5.1. Evolution of local anaesthetics 
In many cultures around the world, the concept of pain in medieval times and up to the early nineteenth century, 
was that of an original sin that needed to be encountered, and the ability to endure it was seen as a sign of 
willpower and virilism.43 A nomadic tribe in Northern Nigeria, up until the present, considers withstanding pain 
from lashes of the cane as a sign of masculinity and as a prerequisite for marrying. 
 
In the course of daily work, dentists were confronted with challenges of how to reduce pain. It is no surprise that 
they were the pioneers of anaesthesiology; Horrace Wells used nitrous oxide in 1844, and William Morton used 
ether in 1846.  Coca leaves were first documented as herbal medicine by Vespucci in the fifteenth century. Much 
34 
 
later with the advent of modern chemistry in 1860, a German chemist, Albert Nieman, isolated and named 
cocaine in its alkaloid form, from erythroxylum coca, (coca plants) that were brought to Europe by Von Scherzer, 
an Austrian in 1850.  Cocaine was the first local anaesthesia used in modern clinical medicine by Koller 
(German), in 1884. He applied it on the eye during ophthalmic surgery.44 The news of the success of this 
intervention sparked the experimentation of cocaine as a local anaesthetic in other regions of the body and wider 
anecdotal applications. It did not take long before the realisation that the toxic effects led to addiction and even 
death - not only among the patients but also medical staff.  
 
Subcutaneous injection of cocaine became popular with the invention of hypodermic needles by Francis Rynd in 
1845.  High concentrations of about 10-30% were used, side effects were devastating and even many physicians 
like Sigmund Freud, a friend of Koller, fell victim to the use of cocaine.44 Negative publicity on the toxic side 
effects of cocaine, resulted in practitioners using lower concentrations of the subcutaneous injection. Amongst 
those who advocated a lower concentration were Haste and Reclus in 1885 who used very low concentrations of 
between 0.1 and 2%.   
 
Despite the reduction in the concentration of cocaine, the search for a safer alternative to cocaine commenced in 
1904 when a German scientist, Einhorn, developed novocaine (which was later called procaine in America). It 
was put it into clinical use by Braun in Germany. However, the drawback with novocaine was the relative 
weakness and the need to combine it with a high concentration of adrenaline. In addition, allergy was a major side 
effect. Stovaine was synthesised in France by Fourneau around the same time. Due to a series of adverse 
effects, search for safer products continued. Cinchocaine (Nupercaine, dibucaine) was synthesised in 1925 by 
Meischer, and introduced for clinical use in 1930. This was closely followed with synthesis of amethocaine 
(pontocaine, tetracaine) in 1928-1932 as a safer alternative, developed by Lofgren and Lundqvist and, between 
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1943 and 1945, at the peak of the Second World War, lidocaine was developed. Lundqvist started by 
experimenting on his own toes. Lidocaine is less allergenic, safe and has a stronger anaesthetic effect than 
novocaine. The amide type of local anaesthesia was later developed between 1957 and 1972 when drugs such 
as mepivacaine (synthesised by Ekenstam and Egner), bupivacaine (synthesised by Ekanstam, 1957 and in 
clinical use by Widman and Telivuo in 1963), prilocaine (synthesised by Lofgren in 1959 and in clinical use by 
Wielding, 1960), and etidocaine (synthesised by Takman, 1971 and in clinical use by Lund 1972) were 
introduced. Drugs, such as ropivacaine (synthesised in 1957 by Ekenstam and clinical introduction only in 1997), 
with few and rare side effects, are now available. Levobupivacaine was commercially prepared in the early 1990s 
and clinical used during 1995-1998. 44, 45.46  
 
 
1.5.2. Pharmacology of local anaesthetic agents 
Local anaesthetics are made from an aromatic lipophilic ring, a hydrocarbon link, made of either an ester or an 
amide, and a terminal hydrophilic amine group. This is depicted in Figure 1.2.47  The characteristics or properties 
of local anaesthetics are mostly determined by changes in the middle link. The amide group [-NH-CO-] are mostly 
metabolised in the liver, such as lidocaine, prilocaine, bupivacaine, ropivacaine, levobupivacaine and 
mepivacaine. This group is more widely used in clinical practice. The ester group, such as cocaine, procaine and 
chloroproccaine, is made of the [-O-C-O-] link and are essentially metabolised by plasma cholinesterase - hence 
more allergic reactions occurred in the ester group.48  
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Fig. 1.2.  Chemical structure of local anaesthetics.47  
 
The mechanism of action of local anaesthetics is at the level of the cell membrane where it blocks inward transfer 
of sodium through the ionophores during the period of depolarisation. The ionophores or channels are cell 
membrane proteins that are important in activation and propagation of action potentials in the nerve endings. 
Other ion channels like calcium and potassium may also be blocked. Local anaesthetic (LA) injection is in acidic 
form. When injected, the perineural environment, which is alkaline, changes it to a base which is lipid soluble. The 
base form allows crossing the axolema, and when it gets intracellular into the axoplasm, it re-ionises into the 
active form for its activity.48 
 
The potency of LA is directly proportional to its molecular weight and lipophilicity; the onset of action of LA is 
dependent on its lipid solubility and the pKa. The higher the solubility and the lower the pKa, the faster the onset 
of action.49 pKa is the negative logarithm of the ionisation (dissociation) constant (Ka) of an acid.  The latter is a 
measure of the acidity of a solution i.e. the pH of a solution in which half of the acid molecules is ionised.  LA that 
has a higher affinity for protein binding has a longer period of efficacy. The duration of action in younger patients 
is shorter than in older patients.  The order of loss of nervous function is pain followed by thermal, tactile, and 
finally motor loss. Myelinated nerve fibres (axons of neurons that are covered with lipid and protein insulating 
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materials) are more readily blocked than those which are non-myelinated. Smaller nerve fibres are more 
responsive to LA block than larger ones.48 
 
1.5.3. Side effects of local anaesthetic agents 
Apart from the blocking of sodium ionophores by local anaesthetics, it equally blocks K, Ca and K ion channels. It 
also binds enzymes, B adrenergic and nicotinic acetylcholine receptors. This explains the many side effects and 
adverse reactions.48  
Ester group LAs, are rapidly hydrolysed by plasma pseudocholinesterase. This is the basis for their reduced risk 
of systemic toxicity compared to the amide group. High levels of LA in the plasma may inhibit the CNS pathways 
by manifesting as tongue numbness, light-headedness, dizziness, visual disturbances, tinnitus and sometimes 
disorientation. If unmanaged, more serious and life threatening side effects of convulsions, CNS and respiratory 
depression may supervene, eventually resulting in cardiac arrest.50 Bupivacaine is more cardiotoxic compared to 
ropivacaine, because the former binds more strongly and longer to the sodium, calcium and potassium cardiac 
muscle ionophores. Symptoms of cardiovascular toxicity start with hypertension and tachycardia and if not 
managed, vasodilatation and negative ionotropic actions ensue, invariably leading to hypotension with 
accompanied arrhythmias and cardiac arrest. Inadvertent injection into the blood vessels may result in CNS toxic 
symptoms as true allergies are not common. Preservatives may be a source of true anaphylaxis. True allergies, 
when they occur, are more likely to be an ester group. This is due to the formation of para-amino benzoic acid, a 
metabolite of esters (amide group is metabolised by hepatic enzymes). The CNS is more susceptible to LA 
toxicity than the cardiovascular system. 51, 52 
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1.5.4. Managing adverse reactions and toxicity 
Most adverse reactions are mild and are allowed to run its course as it rapidly terminates. Further administration 
of the agent should cease. Management of adverse reaction is supportive. The airway is maintained and 
intermittent positive pressure ventilation is given, if necessary. Convulsions are managed by diazepam, 
thiopental, propofol or succinylcholine with ventilation. Hypotension is managed with fluid therapy and adrenalin. If 
cardiac arrest supervenes, adrenalin, intravenous lipid or a cardiopulmonary bypass are options of 
management.53  
 
1.5.5. Common local anaesthetic agents 
Cocaine 
 An extract of erythroxylon coca, called cocaine, is the only naturally occurring local anaesthetic. Cocaine causes 
vasoconstriction in low concentration and vasodilatation in higher concentration, it is therefore unnecessary to add 
vasoconstrictors for mucosa topical use. Cocaine is currently useful as a mucosal anaesthetic prior to 
endotracheal intubation in nasal surgery. It is resistant to catabolism by plasma cholinesterase, a feature that 
potentiates its toxicity .Cocaine is a common drug of abuse and this limits its use in clinical medicine. 51, 55, 56 
 
Lidocaine 
This local anaesthetic is widely used in view of its rapid onset of action, and moderate duration of action and 
potency. When administered at normal dosages, it may be neurotoxic. Duration of action may be up to 3 hours in 
some instances. Lidocaine  non-anaesthetic use includes intravenous administration in ventricular arrhythmia and 
in chronic pain syndrome  56, 57.  
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Mepivacaine 
A hybrid of the xylidine ring of lidocaine and piperidine ring of cocaine was developed called mepivacaine. It has 
lower vasodilatory activity and a longer duration of action compared to lidocaine. When a vasoconstrictor is 
added, a significantly longer duration of action is achieved. It is widely used in dental surgery. 56 
 
Prilocaine 
Of note in prilocaine is the possibility of induction of dose dependent methemoglobinaemia. This appears to limit 
its use despite the high level of pulmonary metabolism resulting in low plasma concentration. The latter is useful 
in that the property makes it relatively safer as a drug of choice in intravenous usage.  
 
Bupivacaine 
Bupivacaine local anaesthetic agent is exceedingly popular. The methyl tail of the piperidine ring of mepivacaine 
is substituted by the butyl ring, a property that enhances its longer duration of action. It is widely used in obstetrics 
as a neuronal analgesia. With the development of levobupivacaine and ropivacaine - drugs which have safer 
cardiovascular profile during inadvertent intravenous injection - bupivacaine is becoming less popular.55, 56, 57   
 
Levopubivacaine 
This is an enantiomer of bupivacaine. Levopubivacaine has similar potency and duration of action as bupivacaine. 
It has a reduced cardiotoxicity compared to bupivacaine hence a better safety profile in clinical situations when 
high level of LA is required.55, 56 
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Ropivacaine 
The vasoconstrictive property of ropivacaine might explain the reduction in its cardiovascular toxicity. It is an S-
enantiomer of the homolog of mepivacaine and bupivacaine. Ropivacaine potency and duration of action is 
comparable to bupivacaine, but with a better safety in the cardiotoxic margin demonstrated in many animal 
experiments and human studies. 55, 56 
 
Drugs that are commonly used with local anaesthetic agents 
Combination of LA with other agents serves to either spare the dosage of LA needed, or to act as an adjunct, 
thereby improving efficacy, prolonging duration and decreasing unwanted side and adverse effects. Such drugs 
may be vasoconstrictors, alpha 2 agonists, bicarbonates, antioxidants or antimicrobials. 
 
Adrenaline is naturally produced by the adrenal medulla and has effects on both alpha and beta adrenergic 
receptors. In view of its potency, a dose that is beneficial in causing vasoconstriction and prolonging the duration 
of action without causing significant side effects, is used (usually 1:200,000 or 5 microgram/ml).The side effects of 
adrenaline often occurs with inadvertent intravenous injection, manifesting as tachycardia or sometimes 
bradycardia when beta adrenergic blockade occurs. Adrenaline can also cause local side effects of terminal artery 
vasoconstriction. When adrenaline is exposed, it loses its potency rapidly. The addition of sodium metabisulfate, 
an antioxidant, is necessary for prolongation of its shelf life. 56 
 
Clonidine is used in combination with LAs as an additive, to potentiate and prolong the effect of LAs especially in 
postoperative analgesia. The addition of bicarbonates in doses that cannot precipitate the LA can also prolong 
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and potentiate its activity by increasing its pH. Antibiotics (methylparaben) are only added for use in wound 
infiltration. 56 
 
New anaesthetic agents are currently being developed. A longer acting derivative of lidocaine, called tonicaine, is 
being studied.  Sameridine, a compound that has LA and opioid receptor agonist properties, is being researched. 
There are naturally occurring neurotoxins such as tetrodotoxin and saxitocin which block sodium ion channels. 
Manipulating liposomal and polymer delivery systems may enhance longer duration of action of local 
anaesthetics. Decreasing the side effects profile of LA is paramount in development of an ideal LA by 
manipulating the molecular structure to target specific receptors. 51 
 
1.6. Measuring outcomes of pain management 
 
The current norm in clinical practice is the need to measure the outcomes of intervention in an evidenced based 
format. Pain management is no exemption to this principle. However, as pain is a sensory-emotional response to 
a noxious stimulus, measurement is subjective. Tools are needed to accomplish this measurement and must be 
valid for a population group, consistent and reproducible. 58 
 
1.6.1. Pain measuring tools 
Means of measuring pain can be classified broadly into unidimensional simple scales and multidimensional 
complex scales. Instruments to be used for pain measurements should be suitable for a specific clinical 
circumstance, specific patient groups and the availability of personnel to administer the tool. A simple 
unidimensional pain scale may be suitable for a busy practice, an elderly patient or an ill patient who can 
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comfortably describe the pain in a simple format instead of a cumbersome and more detailed pain assessment 
questionnaire, such as the multidimensional pain scale. 59 The common simple pain scales are as follows: 
 
Unidimensional pain scales 
Verbal rating scale (VRS) 
A verbal rating scale involves a simple questioning of grading pain from verbal categorical adjectives of no pain, 
mild pain, moderate pain or severe pain, for example. This is of advantage for the very ill or elderly who can easily 
categorise the pain instead of completing a whole body complex format. The disadvantage is the limited choice of 
the descriptive words that may not best describe the patient‘s feeling. For example, a common format is to 
describe pain as ‗mild, moderate and severe‘ that lacks defined description. It yields categorical data and if levels 
of pain are just three, chi square or exact tests can be used for statistical analysis. If there are more than three 
levels, a more complex statistical analysis, like a non-parametric test, can be used.58.59 
 
Numerical rating scale (NRS) 
This is a horizontal line marked 0 to 10 with 0 being no pain and 10, worst pain imaginable (Fig. 1.3). This scale 
can easily be self administered and data recording is simple. It produces non-continuous categorical data like the 
verbal rating scale. 58 
 
0         1         2         3         4         5         6         7         8         9         10 
------------------------------------------------------------------------------------------------- 
No pain                                                                                                  Worst pain imaginable     
Fig. 1.3.  Numerical rating scale 
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Visual analogue scale (VAS) 
The visual analogue scale is a single horizontal 100mm line that begins with no pain and ends with worst pain 
imaginable.58 The VAS is an efficient tool for pain measurement as the patient can visually estimate the point on 
the line where the level of pain lies. The VAS is more sensitive in representing the level of pain although it is more 
labour-intensive and difficult to administer to children and elderly. It generates continuous data making statistical 
analysis simpler to perform and can also be used to measure other emotional responses that come with pain like 
anxiety levels and depression. 60, 61 
 
____________________________________________________________ 
No pain                                                                                                          Worst pain 
 
Fig. 1.4 Visual analogue scale  
 
Multidimensional scales 
Unidimensional pain scales assess pain without considering the multiphase response to injury. They do not 
assess the patient‘s functional impairment, quality of life and effect on patient‘s daily activity. These are what 
multidimensional pain scales address, which are therefore more useful in chronic pain evaluation. 58, 62   Some 
examples of multidimensional tools are mentioned below. 
 
The McGill Pain Questionnaire 
This questionnaire assesses pain intensity and quality in relation to sensory, affective and evaluative dimensions. 
This reliable tool includes the patient‘s perception and distribution of pain. It also incorporates the numerical rating 
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scale. The drawback of this tool is the patient‘s interpretation of adjectives of measurement and the complexity of 
the questionnaire. A short format was created to circumvent the issue of complexity by Melzack in 1987. 58, 59, 67 
 
The Brief Pain Inventory 
This is a multi-dimensional tool that assesses pain intensity and impairment in daily life function and is mostly 
used for assessment of pain in oncology. 61, 68  
 
Emotional tools 
Pain does bring about emotional changes which can be measured in addition to the unidimensional tools. Anxiety, 
depression and anger are some of the emotional response to the pain complex that may need assessment. Tools 
such as Zung depression score; Beck Anxiety and Depression Inventories are examples. 58, 59 
 
Quality of life assessment 
This form of tool assesses the overall impact of pain in all areas of a patient‘s life. A short format is available that 
assesses the patient‘s emotional, mental and social functions apart from assessment of pain. This tool is 
cumbersome and may not be reproducible. 58, 59, 61 
 
 
1.6.2. Post caesarean section pain assessment in obstetrics research 
 
Pain assessment is fraught with challenges as it is a personal and subjective experience, filled with emotions; 
therefore it is difficult to evaluate. This explains the reason for the existence of the numerous tools designed for its 
assessment. There is no ideal tool; a functional tool that fits into a particular clinical situation, which is easily 
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administered by care givers and simple and easily understandable by the patient, will suffice in both clinical and 
research situations.61 Specifically in post-caesarean section research, both unidimensional and multidimensional 
pain tools have been used for pain assessment. A study on 59 patients randomised to local anaesthetic 
ilioinguinal/iliohypogastric nerve block versus placebo used the one-dimensional scale of visual analogue score 
for pain measurement 62.  Another study that randomised 30 women who had caesarean section performed under 
regional anaesthesia into saline, ropivacaine and diclofenac used visual analogue score and opioids 
comsumption for pain measurements.63   An earlier study by Ganta in the 1990s, randomised 62 women into local 
anaesthetic abdominal wall nerve block compared to placebo, used visual analogue pain score as an outcome. 64  
Many other studies on post caesarean section analgesia using adjuvant local anaesthetics, used the visual 
analogue scoring tool for outcome measures.65, 66, 69. 
The choice for visual analogue score as a measuring tool in these studies and many more may appear to be the 
ease of administration and its reproducibility. Multidimensional tools, for example McGill pain questionnaire 67 and 
its modifications, have equally been used in measurement and characterisation of post-caesarean section pain. 
This approach gives a dimension of quality of post caesarean section pain. A descriptive study of 60 women who 
underwent caesarean section had postoperative pain assessed with numeric pain rating scale and modified 
McGill questionnaire. Limitations of physical activities were equally measured with specific instruments.68 
None of these trials reported any technical difficulty in the pain measurement tools that were used.  It thus 
appears that the application of unidimensional or a combination of unidimensional and multidimensional pain tools 
for post-caesarean section pain assessment is practicable and reproducible, even though unidimensional 
assessment is more popular.  
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1.7.  Management recommendations for post-caesarean section pain relief 
 
Post-caesarean section pain management should be a multimodal strategy to minimise pain thereby encouraging 
a positive experience post-delivery and enhancing early bonding between mother and baby. Recommendations 
from various anaesthetic bodies have been published, but the principles remain the same: multimodalism. Below 
is a summary of the Royal College of Obstetricians and Gynaecologists (RCOG) and National Institute for Clinical 
Excellence (NICE) guidelines: 8   
 
Intrathecal analgesia 
Diamoprhine is the drug of choice for intrathecal analgesia. Side-effects include nausea, vomiting and general 
body pruritus. A randomised trial involving 40 women, comparing morphine to diamorphine, showed there was no 
significant difference in the visual analogue scores for pain and total morphine consumption between the two 
groups, however the visual analogue scores for itching and drowsiness were higher in the group that received 
morphine.69  
 
Patient-controlled analgesia 
Women may be offered patient controlled analgesia (PCA) via an intravenous infusion pump or via an in situ 
epidural pump. Different drugs have been compared in efficacy, speed of onset and patient satisfaction.  A 
randomised controlled trial (n=77) compared morphine via an infusion pump device to morphine combined with 
alfentanil. No significant difference was found, either in the overall satisfaction or grading, for the duration of 
analgesia. However, the speed of onset of analgesia was faster in the group that had morphine combined with 
alfentanil. 70  
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Wound infiltration with a local anaesthetic 
Pre- and post laparotomy wound infiltration, sometimes with abdominal nerve blocks, has come up in the last two 
decades, often with conflicting results.71   A systematic review of 26 randomised clinical trials (n=1211), was 
carried out in a range of procedures during laparotomy in general surgery and gynaecology (hysterectomy). There 
were many clinically non-relevant outcomes, and in many others, results were negative. There atre severeal 
reasons that could be attributed to this inconsistent results. The review excluded studies that had peritoneal 
infiltration or instillation and abdominal nerve blocks. It included quasi-randomised trials and  were of diverse 
methodologies using different interventions, dosages and different procedures in general surgery and 
gynaecology. Trials in this review that had local anaesthetic infiltrated above and below the rectus sheet showed 
positive outcomes than in those who had only subcutaneous infiltration. The question of peritoneum and above 
and below the rectus sheet infiltrations were addressed in the thesis by infiltrating the whole of the abdominal 
wall.  The negative outcomes, in many of the trials, were attributed to type II errors. Also, many of the negative 
trials had no power calculations. To circumvent this problem, the clinical trial that was conducted to investigate the 
efficacy of local anaesthetic in caesarean section wound in this thesis, ensured an adequate sample size. Many of 
the studies that were of positive outcomes, in this review, had high methodological qualities. 71 
 
Non-steroidal anti-inflammatory analgesia 
Many clinical trials have noted the opioid sparing effect of non-steroidal anti-inflammatory drugs (NSAID) in 
management of post-caesarean section pain. A randomised controlled trial (n=50) compared the rectal 
administration of diclofenac to placebo post caesarean section. There was no significant difference in the visual 
analogue scores, however, the time to first analgesic request was prolonged in the treatment group compared to 
placebo. 69  Another trial ( n=45),  in which the outcome included the amount of opioid used via a patient-
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controlled epidural anaesthesia, consumed less opioids in groups that had rectal non-steroidal anti-inflammatory 
drugs compared to the control group. There was no difference in the visual analogue scores. 69 
 
The summary recommendation by the Royal College is a combined multimodal strategy of intrathecal or epidural 
diamorphine, post caesarean section patient-controlled epidural or infusion analgesia and a non-steroidal anti-
inflammatory drug, if there are no contraindications. 8 
 
In South African obstetrics practice, these options are available in private health care institutions but are not 
readily available in most government establishments. This may be due to a dearth of expertise and the cost 
involved. In the public health institutions, intrathecal spinal block is usually followed by intermittent intramuscular 
opioids, paracetamol and non-steroidal anti-inflammatory drugs per recta or per oral. 
 
Research recommendations 
The Royal College guidelines state that further research is needed to determine the effect of wound infiltration 
with local anaesthetic at caesarean section on the need for post-caesarean analgesia.8 This recommendation is 
addressed in this thesis. 
 
 
 
1.8. Indications for general anaesthesia for caesarean section 
 
There are still some indications for caesarean section under general anaesthesia in the contemporary obstetrics 
practice, even though it is becoming less common with the availability of better anaesthetic skills.  
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Maternal request for general anaesthetic caesarean is common.  A hospital in Singapore had a 25% caesarean 
delivery rate over a twelve month period of which 20% was performed under general anaesthesia; a high 
percentage of which was due to maternal request. Sixteen percent of the general anaesthetic procedures 
performed were due to epidural failure. 72 Other indications are severe foetal distress, pregnancy induced 
hypertension with haematological derangement, recently administered anticoagulant, and history of adverse or 
allergic reaction to local anaesthetics. Maternal hemodynamic instability, cardiac diseases with poor 
compensation, sepsis along the skin over the vertebrae or generalised sepsis, neuro-muscular conditions such as 
myasthenia gravis and scoliosis were also documented indications. 73 
 
Prevention of mother to child transmission of HIV (vertical transmission) is an important indication for performing a 
caesarean section. Prevention of vertical transmission has been an important intervention in controlling the 
pandemic. Caesarean sections have played a major role in this regard, especially in the affluent communities 
globally.  Any review on caesarean section techniques, may not be complete without mentioning the ever 
increasing rate of operative delivery as a result of strategy of prevention of vertical transmission by offering 
elective caesarean section.  
 
In the 1990s, many small studies were carried out on prevention of vertical transmission of HIV infections in 
newborns but with conflicting results from being beneficial 74 to no benefit 75 and to non significant effects.76  
 
A meta-analysis of fifteen prospective studies carried out by The International Perinatal HIV group in 1999, 
involving 8000 mother-child pairs was done. The findings showed a decrease in the transmission rate of about 
57% after adjusting for other confounding variables like antiretroviral treatment, in women who had elective 
caesarean sections. Mother–child pairs, who had antiretroviral drugs during pregnancy, labour and to the 
50 
 
newborns, had a transmission rate of only 2% 77. When monotherapy was changed to multitherapy, elective 
caesarean section, and non-breastfeeding for vertical transmission prevention, a further reduction to 1% was 
achieved irrespective of viral load. 78  It is of note that vertical transmission was dependent also on viral load prior 
to delivery; with a decrease in transmission rate in women with low viral loads.79   High CD4 count decreases the 
rate of transmission.80 
 
The European AIDS Clinical Society (EACS) guideline of 2008, recommended that caesarean sections be 
performed as prophylaxis in mothers who are HIV positive, except if the plasma HIV viral load is less than 50 
copies/ml at 34-36 weeks of gestation. 81 
 
In the private health sector in South Africa, caesarean sections are routinely offered to all HIV positive women, 
irrespective of the viral load. This may be due to convenience factors especially by private obstetricians, or 
because of other reasons that does not allow for repeating viral load assays at 38 weeks of gestation. 
  
1.9.  Regional versus general anaesthesia for caesarean section 
 
In centres staffed with adequately skilled professionals, caesarean sections are usually performed under 
neuraxail block, thereby preserving the emotional experience associated with the event, and enabling the mother 
to be fully awake during the birth of her child. A 2006 Cochrane Review compared the effects of regional 
anaesthesia with those of general anaesthesia on maternal and infant outcomes (n=1586). The maternal 
hematocrit was higher in patients who underwent regional anaesthesia compared to general anaesthesia and the 
estimated blood loss was lower in the regional anaesthesia group, although there was no significant difference 
between the groups in the need for blood transfusion.  With regard to neonatal outcomes, one-minute Apgar 
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scores favoured the regional anaesthetic group but this difference was not deemed clinically relevant. 82 
Participants in the comparison groups reported similar levels of satisfaction. 
Thus there was no overall advantage in favour of either regional or general anaesthesia for caesarean section; 
the decision is for the mother to make, as long as she is adequately informed of the advantages and 
disadvantages of each method. The availability of standard equipment and skilled personnel is also important. 83    
 
1.10.  Intraperitoneal local anaesthesia in surgery and caesarean section 
 
When the peritoneum is breached, nociceptive signals send impulses to the afferent pathways of the sympathetic 
and parasympathetic pathways.  A diluted anaesthetic lavage solution of 100-300mls of 0.15% lidocaine or 0.10% 
bupivacaine may be poured into the peritoneal cavity during laparoscopy as adjunct to post-operative pain relief.20 
 In the mid 1980s, lidocaine was used in a study on tubal ligation via laparoscopy.  Following dilution of 500mg of 
0.5% lidocaine in this study, the maximum level of serum concentration reached was 2.2 microgram per ml. 84 In 
another study of day-case laparoscopic surgery, the incidence and intensity of referred shoulder pain was 
reduced following laparoscopic lavage with either lidocaine or bupivacaine. 85  
 
Local anaesthetic infiltration may sometimes be indicated in performing a caesarean section.  The communities 
where it has been reported are often resource constrained. Local anaesthetics only, can also be used in rare 
situations when other forms of anaesthesia are medically contra-indicated, as in muscular dystrophy, 
kyphoscoliosis and familial dysautonomia or terminally ill patients. 86-92 It has equally been used in morbid obesity. 
93 The technique of infiltration generally involves infiltration of all layers of the anterior abdominal wall in a 
stepwise manner until the visceral peritoneum is reached. 94, 95 This knowledge that caesarean sections have 
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been performed using local anaesthesia, makes it logical that some form of positive analgesic effect could be 
achieved when local anaesthetic is used as an adjunct to post-operative pain management. 
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1.11. Chromatography and measurement of local anaesthetic serum concentration 
 
The effect of local anaesthetics as an adjunct to post-caesarean section pain management is studied in this 
thesis. Due to the risk of LA toxicity, an assessment of serum LA concentrations following intra-peritoneal 
administration was deemed essential, before embarking on the clinical trial. Serum LA concentrations are 
measured using chromatography. 
 
Chemical analysis was performed by separation of the constituent of a mixture. In 1903, a method of separation 
was invented and described by a Russian botanist, Mikhail Tswett. He separated components of a plant pigment 
by running the mixture through a tube filled with calcium carbonate. The pigments settled in different colour bands 
in the tube segment which he called chromatogram. Chromatography was derived from a Greek word meaning ‗to 
write in colours‘. Subsequently, he applied this method of adsorption chromatography to separate colourless 
substances. It was not until the 1930s when a German, Willstarter, popularised the discovery to the Western 
world. Different techniques of chromatography were developed over the century, some of which are mentioned 
below: 96, 97 
 
1.11.1.  Ion exchange chromatography 
Instead of using calcium carbonate as the adsorbent, electrically charged substances called zeolites were used. 
Synthetic resin was quite popular and was introduced by an American, Spedding for separation. It was employed 
in the Second World War as a component of the survival kit to get non-ionised water from the sea. 
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1.11.2. Paper chromatography 
This was invented by Martins and Synge in the 1940s. Instead of using resins or calcium salts, porous paper 
strips were used as the adsorbent. The mixture substance to be separated is applied to the end of a paper strip 
and a solvent added. The solvent carries the mixture up the paper strip in different colours – this happens at 
different speeds due to the component‘s different physical characteristics. If it is colourless, a reagent is added to 
delineate the colours and each band region is cut out for further analysis. This discovery was of such major 
importance in chemistry that the duo was awarded the Nobel Prize for Chemistry in 1952. Paper chromatography 
was put into use in the discovery of structures of antibiotics, insulin and components of nucleic acid. This 
information was used by Watson and Crick to map out the structure of deoxyribonucleic acid.98,99 
 
1.11.3. Gas chromatography 
This method was invented by Martins and James and uses gas as the adsorbent to separate complex mixtures of 
substances, instead of using a liquid solvent. 97, 98 
 
1.11.4. Thin layer chromatography 
This method makes use of a gel (e.g. silica, alumnia) as adsorbent, which is evenly spread on a glass surface. 
The procedure of separation is fast.100 
 
1.11.5. High performance liquid chromatography (HPLC) 
It is a form of column chromatography whereby the solvent is put under high pressure instead of relying on 
gravity. A faster and better separation is achieved. There are two types of HPLC, the normal phase HPLC and the 
reverse phase HPLC. The former is not often used. The column contains silicon particles which is ionised and the 
solvent is non-ionised. The ionised compounds adhere to the ionised silicon thereby allowing the nonionised 
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compounds to move faster and enable faster separation. In the reversed phase HPLC, the ionised silica is 
modified to non-ionised state by attachment of long carbon chains. This enables the ionised molecules to travel 
faster. It is the most widely used method. 101 
 
High performance liquid chromatography, in its various modifications, is used to measure serum concentration of 
local anaesthetics like ropivacaine.102, 103 The process starts with ultra filtration of the sample using centrifugal 
filtration devices. Aliquot of the ultra filtrate is pumped through high pressure with the solvent. The output is sent 
to a detector for analysis. 101-103 Plasma concentrations of local anaesthetics have mostly been measured with the 
use of chromatography technique. Prilocaine was measured using this technique following intravenous regional 
anaesthesia in the 1960s.104 Plasma concentrations of lidocaine, mepivacaine and bupivacaine were determined 
by high performance liquid chromatography (HPLC) 108. Plasma concentration of ropivacaine was determined by 
a highly selective and sensitive method of HPLC and mass spectrometry 106  
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1.12. Deductions from the literature review and gaps in knowledge  
Local anaesthetics are proven to offer potent pain relief.  Their role as adjuvant postoperative pain relief has been 
accepted by some surgeons and rejected by others as noted earlier in this review of literature.  What is needed is 
a summary of eligible randomised trials to guide clinical practice.  This has been lacking over the decades and is 
justifiably explored in this thesis.    
 Most obstetricians, who believe in the value of local anaesthetic (LA) wound infiltration, inject the LA 
subcutaneously. However, the peritoneum is capable of generating deep-seated and diffuse pain when breached. 
The hypothesis of this thesis is that by wholly infiltrating all the anatomical layers of the anterior abdominal wall, 
including the peritoneum, better analgesia will be achieved.  To my knowledge, there are no randomised clinical 
trials that have compared LA to placebo, using this technique of infiltration. 
Furthermore, little is known about the serum concentrations of LA following intraperitoneal administration or the 
risk of toxicity with this method of LA administration. This obvious gap in knowledge supports the need for the 
serum concentration study of LAs, following peritoneal infiltration and spraying, that forms part of this thesis.   
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CHAPTER TWO 
ROPIVACAINE ABDOMINAL WOUND AND PERITONEAL INFILTRATION IN POST-CAESAREAN SECTION 
PAIN RELIEF – A RANDOMISED CONTROLLED TRIAL 
 
Synopsis 
This chapter explores the effect of local anaesthetic compared to saline placebo for wound infiltration in women 
undergoing general anaesthesia for caesarean section. Ropivacaine was chosen in view of its relative safety. A 
double-blind, randomised placebo-controlled study, with adequate sample size and analysed based on intention 
to treat, was conducted. An innovative technique was used whereby the peritoneum was infiltrated or needle-
sprayed with local anaesthetic. Ropivacaine wound infiltration to all layers of the anterior abdominal wall, including 
the peritoneum, reduced post-operative pain and need for additional post-operative opioids.  
 
2.1. Materials and methods 
2.1.1. Ethics Approval 
This study was approved unconditionally by the Human Research Ethics Committee of the University of the 
Witwatersrand in June 2006 (Protocol Number MO60623). 
 
2.1.2. Hypothesis 
Ropivacaine wound infiltration into all layers of the anterior abdominal wall and infiltrating and spraying of the 
peritoneum, will decrease post operative pain and reduce rescue analgesic requirement in the immediate post 
caesarean delivery period. 
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2.1.3. Intervention 
Treatment group: Patients who consented to participate in the trial that were randomly allocated to receive 7.5 mg 
per ml of ropivacaine (30 mls volume). 
Control group: Patients who consented to participate in the trial that were randomly allocated to receive placebo 
of equal volume. 
 
2.1.4. Recruitment 
Power calculation: In July 2006, a small pilot trial involving seven patients undergoing caesarean section under 
general anaesthesia was carried out. All patients needed rescue opioid within one hour of delivery. For the 
purpose of sample calculation, it was estimated that 90% of women in the placebo group would require pethidine 
within an hour. Thirty eight women in each group were needed to show a reduction from 90% to 60% in the 
intervention group. (Alpha = 0.05, beta = 0.20. Power = 80%) (Epi-Info software, 2002). To compensate for 
possible loss of data, 50 women were randomised into each group. 
Period of recruitment:  In the period between 2003 and 2005 in my obstetrics practice, the average number of 
deliveries per month was 30 women by both caesarean section and normal vaginal births. This amounted to 
about 360 deliveries per year. In this practice, as in many private obstetrics practices in South Africa, about 50% 
of the deliveries were by caesarean section. It was projected that 180 patients would have had a caesarean 
section in a 12 month period. With an assumption of 50% patients agreeing to participate in the trial, it would take 
approximately 13 months to complete recruitment of 100 patients for general anaesthetic caesarean section. 
Recruitment started in August 2006, and ended in December 2007 (a 17 month period). (Figure 2.1). Ten more 
patients were recruited for the pharmacokinetics trial. 
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Fig. 2.1 Flow chart for patients recruited and delivered during the 17 month period of the trial 
 
Inclusion criteria: Participants were 18 years old or more, attending an antenatal clinic with single pregnancies, 
were asked to participate in the trial at about at 34 weeks gestational age. They were without medical risk (ASA 
class I-II), eligible for elective caesarean section and did not have preference for type of anaesthesia - regional 
neuronal block or general.  
 
Total no of 
deliveries = 514
Vaginal deliveries = 
230
Elective cesarean 
sections =243.
Emergency=41
Consented to 
participate in the 
trial = 112
Non-randomized = 
10. Used for serum 
concentration 
study
Randomized 
cesarean section = 
100
Ropivacaine = 50Placebo = 50
Vaginal deliveries 
while waiting for cs 
= 2
Regional neuronal 
block =131
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Exclusion criteria: Patients who failed to give their consent, a history of previous local anaesthetic events, severe 
hypertension in pregnancy with or without proteinuria, cardiac diseases, epilepsy and any other major medical 
disorder of or associated with pregnancy, breech presentation and multiple pregnancies. 
Consent: The patient information leaflet was read to the patients during their antenatal visit at about 34 weeks of 
gestation and they were allowed to ask questions and clarify areas of concern. The leaflet was offered to the 
patient to take home if she wanted to further peruse the details. If the patients agreed to participate, the consent 
form was signed and dated. See patient information sheet and consent in appendix section (Pages 180-206). 
 
2.1.5. Randomisation and theatre procedures 
One hundred random numbers were generated using EPIINFO software by a research unit- Effective Care 
Research Unit - affiliated to the University of the Witwatersrand based in East London, South Africa. The theatre 
matron in the hospital where the trial was conducted, held the random numbers confidential, and prepared one 
hundred cards marked with instructions for drawing up either ropivacaine or normal saline. One hundred 
envelopes were labelled and the corresponding numbered card inserted. The envelopes were thereafter sealed.  
The random list was sealed in another envelope for safe-keeping.  Each time a patient who had earlier consented 
to participate in the trial was brought to the theatre suite, the matron prepared the solution for injection. She wrote 
the patient‘s name against the next number on the register, opened the same numbered envelope, and drew up 
30ml of either 7.5 mg/ml of ropivacaine or saline (depending on what is written on the card).  She replaced the 
card in the envelope and placed them in a sealed container for safekeeping.  She took the syringes with the 
solution to theatre, and squirted the contents into a sterile galley-pot, from which the surgeon drew up the solution 
for infiltration during caesarean section. All patients weighing 65 kg or more received the fixed dose regimen of 
225mg of ropivacaine and those weighing less, received 3mg/kg of ropivacaine or equivalent volume of saline 
placebo. (For brachial plexus block, all women weighing 60kg or more received a fixed dose regimen of 225mg). 
77 
 
 
The clinical trial was conducted in Medi-Clinic Private Hospital, Nelspruit. This is a private hospital setup and it 
was impossible to use a single anaesthesiologist for the trial. The anaesthetists‘ group of eight specialists were 
consulted about the study, and used similar anaesthetic regimen to ensure uniformity as much as possible. All 
patients were monitored by ECG, end-tidal CO2 concentration, blood pressure and pulse rates and O2 saturation. 
Similar methods of induction, maintenance, muscle paralysis, analgesic and reversal of anaesthesia were used. 
In general, the following was suggested as routine for all cases randomised: medications used included- 
Thiopental sodium @ 4mg/kg, Suxamethonium 1mg/kg, Rocuronium 0.3mg/kg, Rapifen 1mg or sufental, if 
needed, Cefoxitin 1gm intravenously 8hrly 3 doses, Syntocinon/syntometrine 1 ampoule, Neostigmine 2.5mg and 
Robinul 0.2mg/ml. At the discretion of the anaesthetist, any other beneficial intervention was used as necessary, 
as long as it was documented. 
 
Post-operatively, rescue Pethidine 100mg 3-4hrly and Diclofenac 75mg intramuscularly 12 hourly were used. 
Tramadol/acetaminophen 2 tabs 6hrly from Day 1 were used as necessary. 
 
Surgical procedure: Patients were prepared and draped.  The Pfannenstiel incision was preferred unless previous 
midline sub-umbilical incision was performed. A routine lower segment caesarean section was performed, baby 
delivered, syntocinon® 5 units given and the placenta delivered by cord traction. The uterus was closed by a 
single layer of inverted figure of 8 vicryl 1 suture or continuous suture. Haemostasis was secured with further 
single sutures. Uterovesical visceral peritoneum on the anterior uterine wall was left unsutured. Five millilitres of 
the 30mls of pre-prepared solution in the galley-pot, was drawn into a 20mls syringe attached to a 23 gauge 
needle and needle-sprayed on the unsutured peritoneal edges. The receded parietal peritoneal edges were 
sought for and pulled into view with several artery clamps. This was to allow visualisation that enhanced direct 
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infiltration of another 5 millilitres (mls) of the prepared solution into the parietal peritoneum. The parietal 
peritoneum was also left unsutured. The rectus muscles were approximated with 2 interrupted vicryl 1 
(polyglycolic) sutures. The rectus aponeurosis edges were infiltrated with another 10 mls of the prepared solution 
and the edges sutured with vicryl 1 cutting needle. The remaining 10 mls was infiltrated subcutaneously along the 
superior and inferior skin wound edges and the skin approximated with subcutaneous absorbable vicryl 2. 0 
sutures. All patients had 225mg of ropivacaine except those who weighed 64kg or less that received a volume 
equivalent to 3mg/kg body weight. The time of completion of skin wound closure was recorded. All caesarean 
sections were carried out by the same surgeon, the student. 
 
2.1.6. Pain Assessments 
Pain assessment was routine standard for Medi-Clinic post-operative patients using the numerical rating scale 
and the verbal rating scale. Despite this, eight Medi-Clinic employed midwifes who were on day and night shifts, 
were trained on pain assessments, meticulous record keeping and other requirements of the protocol. They were 
continuously retrained, and the ideals of conducting a proper clinical trial emphasised on a regular basis. This 
ensured standardisation. Taking into cognisance that this study was a double blind randomised trial, any 
systematic difference in pain scoring between observers should be evenly distributed between the two groups.   
The first pain assessment was done at 15 minutes of skin closure, in the recovery room. One hundred milligrams 
of pethidine was prescribed by the anaesthetist 3-4 hourly intramuscularly as necessary to all patients. Pain 
assessments continued in the ward for 24 hours. 
If at any stage the doctors looking after the woman needed to know what the injection was (for the purpose of her 
care), the theatre matron was asked to ‗unblind‘ the treatment and mark down on the register that the treatment 
was ‗unblinded‘.   
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2.1.7. Outcome measures 
The primary end-points were severe/unbearable pain at 60 minutes post-operative or need for rescue pethidine 
within 60 minutes post caesarean section.  Secondary outcome were pain scores, oral analgesic (tramadol 
32.5mg/ acetaminophen 325mg) requirement, and side effects. 
 
2.1.8. Follow up 
Fifteen minutes, 1 hour, 2 hours, 4 hours 8 hours, 16 hours and 24 hours after closure of the skin, a pain 
assessment questionnaire using a three-level verbal rating scale of no pain, moderate pain and 
severe/unbearable pain was administered. A second pain scale called numerical rating scale was administered at 
the same time. The visual analogue scale correlates well with a verbal 11-point numerical rating scale. 14 The 11-
point pain scale ruler was routinely used in Medi-Clinic Hospital, Nelspruit with 0 as no pain and 10 as the worst 
pain imaginable. These simple pain scales were administered by attending midwives. The patients were shown 
the scale and asked to state their pain score at a particular time, from 0-10. The midwives, who were selected and 
have been re-trained for the trial, were told not to seek for any intervention that will unblind the allocation like 
touching the wound edges. 
 
Narcotic analgesics were administered as necessary and the pain assessment questionnaire, with other 
information on the data collection form were completed at intervals. Most women were expected to be discharged 
on day two post-operative. Post surgical follow up was routinely done 6 weeks post-operatively unless wound 
infection supervenes or if there is any other problem which the patients were advised to report. 
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2.1.9. Data collection 
Pre-randomisation data: Consents to participate in the trial were previously obtained during the patient‘s antenatal 
visit. (See appendix) and were clearly identified. Pre-randomisation data that included the patient‘s age, weight, 
parity and the hospital identification stickers were collected on the operation day, in the labour ward prior to the 
caesarean section by the investigator. 
Outcome data: These were collected by the investigator, the theatre recovery nurses and the labour ward 
midwives. The investigator gave advice when there was a need for clarification. The outcome data included verbal 
rating scales and numerical rating scales, use of pethidine, rescue tramadol/acetaminophen analgesic 
requirement, pyrexia above 38 degree Celsius, vomiting, pruritus and wound sepsis.  
 
2.1.10. Statistical analysis 
Results were entered into Microsoft office excel 97-2003 spreadsheet and cross checked for errors. It was 
imported and analysed with a statistical software package, Epi-info version 3.4.3, 2007. 
Data entry and checking were continuous and queries were followed rigorously to ensure that clarification was 
done without delay. The analysis was on an intention-to-treat principle with comparisons made between 
ropivacaine abdominal wound and peritoneal infiltration and placebo, for primary and secondary outcomes.  
Mantel Haenszel analysis method was used for comparison of dichotomous data which was expressed as 
percentages and relative risks with 95% confidence intervals.  Comparisons of non-categorical data were by 
Mann –Whitney two-sample test (equivalent to chi square). Median and range of data were calculated and the 
degree of significance determined by p values below 0.05. 
Primary outcomes of clinical study: Severe /unbearable pain within 60 minutes post-caesarean section and need 
for pethidine administration within 60 minutes of procedure. Secondary outcomes were verbal rating scales and 
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numerical rating scales, use of pethidine, rescue tramadol/acetaminophen analgesic requirement, pyrexia above 
38 degree Celsius, vomiting, pruritus and wound sepsis.  
 
2.1.11. Quality control procedures 
1. Data checking and entry of completed data collection forms were meticulous. Data sheets and all other 
documents were stored for future reference, audits and queries.  
2. Double-blinding with identical-looking placebo (saline) will avoid any bias at entry to the trial and during the 
monitoring of patients and assessment of outcomes.   
3. Randomisation took place shortly before the patient was taken to the operating suite.   
4. Good Clinical Practice (GCP) procedures (WHO 1995) were followed. 
5. Data were analysed and reported on an intention-to-treat basis.  
 
2.2. Results 
A total of 2868 patients were delivered at Nelspruit Medi-Clinic obstetrics unit between August 2006 and 
December 2007 during the trial period, out of which the author delivered 514 patients.  This represented 18% of 
all deliveries in the unit. Of the 514 patients delivered by the author, 284 were by caesarean section (55.2%). Of 
these, 243 had elective Caesarean section (47.2%). The rate of caesarean delivery in the unit by all obstetricians 
during the trial period was 60.3 %.  
 
 Prophylaxis against mother to child transmission of HIV was the main indication for performing elective 
caesarean section by the author (46.3%) (Table 2.1). The average gestational age when blood was taken for viral 
load counting and CD4 count was 32 (SD 6.4) weeks. The average viral load was 85,740 with the lowest load of 
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1,732 recorded at 38 weeks and the highest 1,300,000 recorded in a patient at 25 weeks of gestation. There were 
no patients who had a third trimester viral load of less than 1000.   The average CD4 count was 399 (SD 265).   
 
The baseline data are depicted in Table 2.2 and 2.3. Missing data are indicated by the N values (total of 50 
women in each group).The two arms of the study, ropivacaine infiltration and saline control were comparable in 
respect to age, height, weight and parity. Nine women had body weight between 60kg and 65kg, five in the 
ropivacaine group and four in the control group. None weighed less than 60kg.  Overall, there was no significant 
difference in the baseline characteristics.  
 
Twenty four out of 50 women required rescue pethidine within 1 hour  or experienced severe pain at one hour 
post caesarean section in the ropivacaine group compared to 47 out of 50 women in the saline control group (RR 
0.51, 95%CI 0.38-0.69) (Table 2.4). There was a significant reduction in the numerical pain rating scale (NRS) up 
to 2 hours in the treatment group compared to the control [median (range) 2, (1-3) versus 2(1-10)].  (Table 2.5) 
 
 Six out of 50 patients in the ropivacaine group had severe or unbearable pain at 15 minutes post-operative 
compared to 31 of 50 women who had saline placebo (RR 0.19, 95% CI 0.09-0.42). The reduction in pain 
continued up to 2 hours postoperative. Six out of 50 patients in the ropivacaine group needed at least 75 mg of 
intramuscular rescue diclofenac injection in the first 24 hours compared to 30 out of 50 in the saline group. 
Tramadol/acetaminophen tablets consumed in the ropivacaine group were 236 versus 334 in the control group. 
[Median (range], 4(3-12) versus 7(4-20); p=0.001]. 
 
One patient in each group had vomiting and pruritus. No patients, out of the 49 in the ropivacaine group, had 
wound infection but 3 out of 50 in the saline placebo group had septic wounds. (RR 0.15, 95% CI 0.01- 2.75). 
83 
 
There was no cardiovascular or central nervous system event. No patients reported either overall poor pain 
control or poor general post-operative satisfaction. There was no need to unblind the group allocation during the 
trial. 
 
 
 
Table 2.1 Indications for elective caesarean section amongst trial participants (N = 110) 
Indication n % 
Prevention of mother to child transmission of HIV 51 46.3 
Mother‘s choice 17 15.4 
Previous Caesarean (with or without HIV) 22 20 
Antenatal pelvic disproportion (big baby, etc) 4 3.6 
Abnormal Doppler (Reversed end diastolic flow) 3 2.7 
Impaired foetal growth with oligohydramnios 3  2.7 
Bad obstetrics history.   2 1.8 
Severe genital warts 2 1.8 
Previous vertebral operation  1 0.9 
Placenta praevia 2 1.8 
Previous pelvic prolapse surgery with or without use of mesh 2 1.8 
Previous abdominoplasty 1 0.9 
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Table 2.2 Baseline data: ropivacaine versus placebo [expressed as means and standard deviations  
(SD)] 
 Ropivacaine Saline placebo  
N Mean  SD N Mean  SD P value 
Age (years) 50 29.66 5.26 50 30.54 6.09 0.44 
Weight (kg) 46 79.52 16.76 48 79.68 14.25 0.75 
Height (cm) 41 160.92 10.71 36 160.41 6.90 0.80 
 
 
Table 2.3. Baseline data: ropivacaine versus placebo [expressed as proportions (n/N)  
and percentages(%)] 
                                       Ropivacaine Saline placebo  
n/N % n/N % P value 
Pfannenstiel incision 49/50 98 48/50 96 0.57 
Primiparous 15/50 30 14/50 28 0.83 
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Table 2.4. Pain outcome data of participants: ropivacaine versus placebo [continuous data expressed as 
median (range)] 
 
 
 
Ropivacaine Saline placebo  
Outcome N Median (Range) N Median (Range) P value 
Pain score 15min 50 1(1-3) 50 3 (1-8)) 0.000 
Pain score 1hr 50 2(1-3) 50 3 (1-5) 0.003 
Pain score 2hrs 49 2(1-3) 49 2 (1-10) 0.008 
Pain score 4hrs 50 3 (0-8) 49 5(1-10) 0.06 
Pain score 8hrs 50 3(0-8) 50 3(0-9) 0.25 
Pain score 16hrs 50 2(1-5)  46 2(1-4) 0.16 
Pain score 24hrs 49 2(1-6) 48 2 (0-3). 0.32 
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Table 2.5  Dichotomous outcome data of participants: ropivacaine versus placebo [Expressed as 
numbers (n=no. of events, N=total number), percentages and relative risk (RR) with 95% confidence 
intervals (95% CI)] 
 
 Ropivacaine Saline placebo   
Outcome n N % n N % RR 95%CI 
Severe pain 15min 6 50 12 31 50 62 0.19 0.09,0.42 
Severe pain 2hrs 4 49 8 13 49 27 0.31 0.11,0.88 
Severe pain 4hrs 9 50 18 15 48 31 0.58 0.28,1.19 
Severe pain 8hrs 10 50 20 14 50 28 0.71 0.35,1.45 
Severe pain 16hrs 6 50 12 11 46 24 0.50 0.20,1.25 
Severe pain 24hrs 5 49 10 6 48 10 0.82 0.27,2.50 
Temp above 38 0 49 0 0 50  Not estimable 
Vomiting 1 49 2. 1 49 2 1.00 0.06,15.53 
Pruritus 1 48 2 1 48 2 1.00 0.06,15.3 
Septic wound 0 49 0 3 50 6 0.15 0.01, 2.75 
Pain satisfaction 
poor (not satisfied) 
0 49 0 0 47 0 Not estimable 
General 
satisfaction poor 
0 49 0 0 50 0 Not estimable 
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2.3. Discussion 
Caesarean section rates in most regions of the world have been increasing. In the author‘s practice, during the 
period of this study, the caesarean section rate was 54%.  The caesarean section rate performed by the entire 
unit in the hospital, including all obstetricians, was 60% of total deliveries.  These figures are similar to the 
caesarean section rates in other private hospitals in South Africa. 1,2 
 
 The most frequent indication for caesarean sections in the trial was prophylaxis against mother to child 
transmission of HIV. The province of Mpumalanga where the study was done had the highest HIV incidence in 
South Africa of 2.4 % per year in 2005. The HIV prevalence amongst South Africa pregnant population was 37% 
(95% CI, 24.9-51.0) in 2005 3 - a year before the commencement of this trial. 
 
In this clinical trial, caesarean sections done for HIV prevention of vertical mother to child transmission accounted 
for 46%.  Most general practitioners in Nelspruit area referred HIV positive patients, who had medical insurance, 
for specialist assessment and delivery by caesarean section. This accounted for the high rate of HIV positive 
expectant patients in the practice. Many of these patients were referred after 30 weeks gestation. 
 
An increased rate of caesarean delivery in South African obstetrics practice has followed the European and 
American recommendation of offering caesarean delivery in women with viral load of greater than 1000 copies 
per ml in the last trimester. There were no patients with undetectable viral copies that participated in the trial. This 
might be due to newly diagnosed HIV infected patients that presented late in pregnancy, or if earlier diagnosed, 
were never on antiretroviral drugs. It may also be due to poor compliance. 
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Patients‘ choice was the second highest indication for caesarean section at 15.4% in this study. The reason(s) for 
each patient‘s decision on a caesarean section was not documented in the trial. Many reasons have been 
attributed to the patients‘ choice for elective caesarean delivery without any medical reason. The fear of repeating 
of a previously traumatic delivery experience or outright fear of vaginal delivery amongst primigravida is a widely 
recognised reason. 4 
 
Other reasons for patients to request elective operative delivery are convenience to parents and obstetricians, 
prevention of perineal damage and a better reassurance for a lesser risk of morbidity to baby and avoiding pain in 
labour and during delivery.5   There is much debate amongst health care givers and parents, as to whether 
patients should be allowed to choose how they want to be delivered. However, in most South African private 
obstetrics practices and also in the unit where this trial was carried out, patients‘ request for a caesarean section 
for non medical reasons is often granted as long as the obstetrician discusses the pros and cons of the procedure 
with the mothers. 
  
Post caesarean section pain is mediated not only by somatic nerves but also by a visceral component. 
Intervention at the level of the peritoneum may increase the efficacy of analgesia and to the author‘s knowledge 
this has not been explored in the context of post caesarean section analgesia. In a study where local anaesthetic 
was instilled into the peritoneum after laparoscopic surgery, morphine requirement was less compared to when 
saline placebo was administered. 6 Extrapolating from this trial, it is reasonable to assume that sprinkling or 
infiltrating local anaesthetics onto the peritoneal surfaces and infiltration of the rectus aponeurosis and the 
subcutaneous tissue, during planned caesarean section, may alleviate post-operative pain.  
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The choice of anaesthesia for this study was ropivacaine. It is an agent of the amide group which has a long 
duration of action. The mechanism of action is through a reversible blockade of nerve impulse across the fibres by 
preventing sodium ions diffusion into the neuronal cell membranes.7  
 
 
Fig. 2.2.  Molecular structure of ropivacaine.  (Reproduced from Wikimedia Commons) 
 
Ropivacaine has intrinsic vasoconstrictor activities because of its‘ slow diffusion away from site of infiltration. For 
this reason, vasoconstrictors are not added to ropivacaine and the delay in local diffusion makes it a lower risk for 
cardiovascular side effects in the event of inadvertent intravascular injection. Due to this better safety profile, 
ropivacaine was used for the trial.  At higher concentration, ropivacaine produces surgical anaesthesia and at 
lower concentration it produces analgesia. 7   Pre-incision infiltration was not considered because of the risk of 
drug transmission across the placenta to the foetus.  Ropivacaine is becoming widely available in view of its 
safety, and is comparable to bupivacaine in cost. 
 
The recommended dosage by AstraZeneca pharmaceutical limited of ropivacaine for minor nerve block and 
wound infiltration anaesthesia, in an adult weighing 60kg or more, is 225mg of 7.5mg/ml solution.7 The dosage 
chosen for the clinical trial was 225mg i.e. three ampoules of 75mg/10ml. It is less than the 300mg maximum 
dose recommended at a single infiltration for major nerve block such as brachial plexus.  A dose of 3mg/kg body 
weight was used for women weighing less than 64kg (60mg in the drug insert but 4kg added to compensate for 
the immediate weight loss following delivery accounted for by the foetus, placenta, amniotic fluid and blood). 
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 A trial of 30mls of 7.5mg/ml solution ropivacaine equivalent to 225mg regardless of the patient weight has been 
conducted for instillation during laparoscopy. 6   Many other trials were conducted using a fixed dose regimen in 
surgery and gynaecology. 6, 8-14   The advantage of a fixed dose regimen will be the ease of application in a 
clinical setting. The site of administration and action is local, but systemic absorption and plasma concentration, 
which is proportional to the weight, may be of importance in ensuring drug safety. A pharmacokinetic study was 
performed with this regimen and the report given in chapter 3.  
 
As alluded to earlier in the review of literature, there is still a place for caesarean section under local anaesthetic 
infiltration but there is no known trial on the dose of local anaesthetic to use. The anaesthetic dosage of 225mg 
(7.5mg/ml solution) ropivacaine used in this trial, by extrapolation, may be used for infiltration anaesthesia in 
patients requiring caesarean section by local infiltration only.  
 
It is now a well accepted practice that general anaesthesia is not the first choice of anaesthesia for caesarean 
section, but indications do exist. Patients‘ preferences should be respected, 15 and certain patients may not be 
suitable for regional anaesthesia. The patients who agreed to participate in this trial were those who were due for 
caesarean section under general anaesthesia and who consented to random allocation to the study groups. 
According to this study, patients who were operated upon under general anaesthesia, benefitted from the 
infiltration of all layers of the abdominal wall and infiltration/spraying of the peritoneal surfaces, with 7.5mg/ml 
ropivacaine solution (225mg). The route of administration for this trial was through direct wound infiltration as 
opposed to abdominal nerve blocks. This makes the intervention more widely implementable, as abdominal wall 
nerve blocks require specialised training, bearing in mind that most caesarean sections in resource-constrained 
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settings are carried out by non-specialists. The simplicity of this intervention will make it widely acceptable and 
may change practice in many health care facilities worldwide. 
 
The advantage of pain relief offered by complete wound infiltration and peritoneal spraying gradually diminishes 
as time progressed. This was not unexpected as the onset of action of ropivacaine is 1-15 minutes and the 
duration of action is 2-6 hours.7   the maximum benefit in this study was seen at 15 minutes after skin closure.  
The amount of pethidine used in the first hour was significantly reduced in the ropivacaine group.  By four hours, 
the difference was not statistically significant, probably due to dilution of the early effects, as the ropivacaine wore 
off over time.  In addition, the requirements for diclofenac and tramadol/acetaminophen analgesia were reduced. 
The early positive effect on the need for additional post-operative analgesia may be important to facilitate bonding 
of the mother with her newborn.  
 
A significant proportion of post-operative pain may come from superficial structures, but peritoneal pain may also 
be of importance. 16   Anaesthetising the peritoneal surfaces with ropivacaine may be partly responsible for the 
positive result in this trial compared to studies where only the skin and subcutaneous tissues were infiltrated with 
different outcomes.  This assumption will need to be confirmed in a study comparing the traditional superficial 
wound infiltration with wound infiltration down to the peritoneum. The decision to compare the clinical outcome of 
local anaesthetics to all abdominal layers and peritoneum with placebo, emanated from the fact that no study, 
according to the author‘s knowledge, and as at the time of commencement of this trial in 2006, had explored and 
documented this approach in caesarean section analgesia. The technique is different from that in which only the 
skin and subcutaneous tissues were infiltrated. The finding will thus serve as a base line for comparing other 
clinical applications in future trials.  
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A secondary objective of this study was to evaluate the safety of 225mg ropivacaine - which may be used for 
performing caesarean section in those rare instances in which surgery is performed under local anaesthetic 
infiltration.  There was no allergic, cardiovascular or central nervous system side effect amongst the ropivacaine 
exposed patients, or those that were randomised to receive placebo. It should be noted that a clinical trial of this 
nature, which has side effect as a secondary end result, will require far more participants than 100 patients. The 
small sample size is a limitation to the study. There has not been any trial, to our knowledge, that has addressed 
the dosage for carrying out caesarean sections under local anaesthetic infiltration. This may serve as a guide for 
such cases or a future trial.  A lower local anaesthetic dosage, with higher volume, may be adequate in patients 
having caesarean sections under general anaesthesia, but this too would require further clinical study. 
 
This trial did not evaluate events around breastfeeding as an outcome, because the indication for the majority of 
the patients, who were electively scheduled to have caesarean sections, was prophylaxis against mother to child 
transmission of Human immune Deficiency Virus (HIV). Thus most would not have been planning to breastfeed 
their babies. 
 
Time of discharge was not evaluated because all patients recruited for the study paid their medical bill through the 
medical insurance companies. These companies normally advise on the number of days for hospitalisation.  To 
avoid unnecessary financial burden on the patient, we strictly followed the advice of the medical insurance for 
suggested day of discharge, unless medically indicated, such as in cases of severe pain or wound breakdown. In 
this trial, there were none reported. To assess the date of discharge as an outcome for evaluating the pain relief 
would therefore not be of use for this study. 
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A sub-group analysis based on patients who had previously had their babies delivered by caesarean section, did 
not alter the results. The trend to performing caesarean sections under regional anaesthesia, with improvement in 
awareness, training and skill, will continue to increase. Meta-analysis in the following chapter showed benefit 
when local anaesthetic wound infiltration was used as adjunct in women undergoing regional block. It will be 
worthwhile to explore infiltrating local anaesthesia down to the level of the peritoneum in women with regional 
anaesthesia and comparing it to women who will have local anaesthetic administration to the subcutaneous and 
skin only. This will define the role of peritoneal administration. The same is applicable to women who have 
general anaesthesia. 
 
2.4. Conclusion 
 Ropivacaine wound infiltration and peritoneal spraying as post-operative analgesia in elective caesarean section 
on single pregnancy at term, reduced the need for narcotics and non narcotic analgesics and severe pain in 
patients undergoing general anaesthesia. This novel and simple technique has clearly established that local 
anaesthetic administration to all layers of the abdomen down to the utero-vesical peritoneum is superior to 
placebo. This could serve as a baseline for further studies and could be used as a routine adjuvant pain-relief 
intervention in patients undergoing general anaesthetic caesarean sections worldwide. Use of a lesser 
concentration and larger volume may be worthy of further study. 
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CHAPTER THREE 
ROPIVACAINE SERUM CONCENTRATION FOLLOWING CAESAREAN SECTION WOUND AND 
PERITONEAL INFILTRATION – A PHARMACOKINETIC STUDY 
 
Synopsis 
Local anaesthetics have been employed over the decades to relieve post-operative pain. Ropivacaine wound 
infiltration, including peritoneal infiltration or spraying, for caesarean delivery pain relief is a new advancement. 
Since drugs may be optimally absorbed by the peritoneum, the peritoneal route of administration has the potential 
to reach toxic serum levels. No pharmacokinetic studies of local anaesthetic agents have been done with this 
route of administration. For this study, serum concentrations were determined at various intervals following the 
administration of 225mg of ropivacaine. The maximum serum concentration of ropivacaine was within safe levels 
and similar to levels reached following epidural caesarean deliveries. 
 
 
3.1. Study objective 
To determine the maximum serum concentration of Ropivacaine following administration of 225mg of 
Ropivacaine through all layers of the anterior abdominal wall, including the peritoneum, in patients undergoing 
general anaesthetic caesarean section. 
 
3.2. Methodology  
Institutional approval was obtained from the Committee for Research on Human Ethics subjects, University of the 
Witwatersrand in 2006. The study was carried out at the Nelspruit Medi-Clinic Private Hospital in 2007. Out of the 
110 patients recruited for the clinical trial, as stated in Chapter 2, the last (consecutive) ten patients were selected 
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to participate in the trial during antenatal visits. The patient information leaflets and consent forms were handed 
out to consenting patients, and signed. 
 
Immediately after the patients were put under general anaesthesia, 21-gauge preheparinised intravenous cannula 
was inserted in the antecubital veins for blood collections. Blood samples were collected at time 0 in a 5 mls plain 
tube as base line. After the baby and placenta were delivered, 225mg (30mls volume) of ropivacaine was 
injected/sprinkled into the wound. Five mls sprinkled into the visceral peritoneum, 5 mls into the parietal 
peritoneum, 10 mls into and above the rectus sheath and 10mls subcutaneously under the skin. The time of 
commencement of ropivacaine injection was noted. At 15 minutes, 30 minutes, 1 hour, 2 hours, 4 hours, 8 hours, 
16 hours and 24 hours post caesarean section, blood was drawn for plasma concentration of ropivacaine. 
The blood samples were centrifuged at a 4000 revolutions per minute using Biofuge Heraeus Centrifuge over 10 
minutes at room temperature. The serum separated was stored at a temperature of -20 degree Celsius. The 
specimens were placed in a refrigerated storage facility within 60 minutes of drawing the blood.  Serum 
concentrations were determined using reversed high-performance liquid chromatography, by a 2005 described 
method.1  A 500 micro litre of the plasma sample was placed in a 10 mls siliconised tube. 100 micro litre of 
internal standard made of bupivacaine and 250 micro litre of 0.1M of sodium hydroxide were added and mixed. 
To this mixture was added ethyl acetate used for extraction of the bupivacaine (internal standard) and 
ropivacaine. The mixture was centrifuged for 6 min at 1500g. The upper organic phase was removed to another 
tube and another 2ml of ethyl acetate added and centrifuged. Both organic phase samples were evaporated to 
obtain dry samples. The evaporation was carried out using a stream of nitrogen at a temperature of -40 degrees 
Celsius. The extract was mixed with mobile phase solvent (100 micro litre) and 25 micro litre aliquot forcibly 
injected into the HPLC machine at a flow rate of 0.8ml/min.  The HPLC machine, Waters Separation 2690 model 
with a Photodiode array detector, consisted of a pump, an ultraviolet detector set to 215 nm and an integrator. 
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The mobile phase solvent was a mixture of acetonitrite, methanol and a buffer of phosphate adjusted to a pH of 
4.0  
 
 
3.3. Results 
In one patient, the baseline sample at time 0, showed presence of ropivacaine. This was assumed to be due to 
incorrect labelling of the samples. The samples from the patient were omitted from analysis.  
Data from the remaining nine women was analysed.  Samples were not obtainable at all the time intervals. The 
mean parity (SD) of the women was 2.6 (1.5), age 35.4 (2.9) years, weight 79.67 (18.3) kg and mean height was 
162.4 (5.0) cm. There was no patient who weighed less than 65kg. The maximum serum concentration (Cmax) of 
ropivacaine following administration of 225mg via this route was 1553 (SD 793) ug/L obtained at 30 minutes 
following administration (Tmax). The concentration fell gradually over 24 hours.  The missing data was 
responsible for variations in n. On several instances, patients in the trial declined taking blood samples while 
sleeping, especially at night or in the early hours of morning.  
 
Table 3.1 Mean concentration of ropivacaine (µg/L) over time  
Time (minutes) 0 15 30 60 120 240 480 960 1920 
No. of participants 9 9 9 8 9 7 7 7 6 
Mean (ug/ml) 0 1357 1553 1300 1030 980 707 645 582 
Standard deviation 0 751 793 350 429 231 528 351 690 
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Figure 3.1 Mean concentration of ropivacaine (ug/ml) versus time (minutes). 
 
3.4. Discussion  
A pharmacokinetic study of plasma levels following intraperitoneal instillation of ropivacaine in combination with 
abdominal wall infiltration at caesarean section has not, according to the author‘s knowledge, previously been 
performed. The maximum plasma concentration (Cmax) reached within 30 minutes of drug administration, implies 
the rapid absorption of ropivacaine following this route of drug administration. This rapid absorption is postulated 
to be due to peritoneal administration of the local anaesthetic agent and exposure of the agent to open blood 
vessels breached during surgery.  
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Following brachial plexus block after a dose of 300mg ropivacaine, the Tmax (SD) was 54(22) minutes with a 
Cmax (SD)of 2300 (800) µg/L 2 The Cmax  of ropivacaine( 1553+-793 µg/L) in this study fell between  levels  
reached after 72 hours of continuous epidural  infusion  after a cumulative dose of 2075+-206mg ( 2800+/-SD 
500µg/L), and  following 7.5mg/ml ropivacaine epidural block for caesarean delivery at  1100 (200) µg/L. 1 The 
toxic serum level of ropivacaine is not well characterised but the safety margin is between 1000 – 3000 µg/L, 
even though levels as high as 5000 µg/L has been reached without adverse effect. 3   The study limitation was 
the missing data due to patients who declined giving blood samples while sleeping at night. The results indicated 
that the dose used would be safe to use and even for those having caesarean delivery under local anaesthetic 
infiltration only.  
 
The number of patients who participated in this study was too small to establish if there is any correlation between 
the individual patient‘s weight and the maximum serum concentration. 
 
3.5. Conclusion 
The maximum concentration of ropivacaine using a dosage of 225mg by infiltration through all layers of the 
anterior abdominal wall incision, including spraying of peritoneum at caesarean section, was 1553 (SD) 793 µg/L 
/L. This is well below levels reached following brachial plexus block and 72 hours of continuous epidural infusion. 
This level falls within the safety range in humans. 
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CHAPTER FOUR   
LOCAL ANAESTHETIC WOUND INFILTRATION AND ABDOMINAL NERVES BLOCK DURING CAESAREAN 
SECTION FOR POSTOPERATIVE PAIN RELIEF – A SYSTEMATIC REVIEW   
Synopsis 
This chapter of the thesis dealt with a summarised analysis of all suitable trials, including the clinical trial above, in 
a systematic review, to advise health care providers on the role of adjuvant local anaesthetic infiltration in post- 
caesarean section analgesia. This review was done and published under the Pregnancy and Childbirth group of 
the Cochrane collaboration, United Kingdom and followed the guidelines of Cochrane systematic review. Twenty 
trials involving 1150 patients were analysed, it was concluded that local anaesthetic wound infiltration and 
abdominal nerve blocks as adjuncts to regional and general anaesthesia, were of benefit in caesarean section 
pain relief by reducing opioid consumption. Non-steroidal anti-inflammatory drugs as an adjuvant conferred 
additional pain relief. The format of this chapter, including tables and referencing, follows the Cochrane 
conventions. This explains some of the disparity in presentation of this chapter as compared to previous ones. 
The systematic review has generated considerable interest in both scientific and in the lay press worldwide. This 
may change clinical practice and contribute to the advancement of medical knowledge.  
 
Abstract 
Caesarean section delivery is becoming more frequent. Childbirth is an emotion-filled event and the mother needs 
to bond with her newborn baby as early as possible. Any intervention that leads to improvement in pain relief is 
worthy of investigation. Local anesthetics, either on their own or in combination with opioids or non-steroidal anti-
inflammatory drugs, have been employed as an adjunct to other post-operative pain relief strategies. Conflicting 
reports were noted. 
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Objectives   
To assess the effects of local anesthetic agent wound infiltration/irrigation and/or abdominal nerve blocks on post 
caesarean section pain, and the mother's well being and interaction with her baby. 
Search methods   
The Cochrane Pregnancy and Childbirth Group's Trials Register was searched (April 2009). 
Selection criteria   
Randomised controlled trials of pre-emptive local analgesia during caesarean section. 
Data collection and analysis   
The student extracted data. One of the supervisors checked the data (GJH). The data published by the author, 
was checked for eligibility by an independent Cochrane reviewer. 
Results   
Twenty studies (1150 patients) were included. Patients, who had a caesarean section performed under regional 
analgesia and had wound infiltration, showed a decrease in morphine consumption at 24 hours (SMD -1.70mg; 
95% confidence interval (CI) -2.75 to -0.94) compared to placebo. 
In patients under general anesthesia, with caesarean section wound infiltration and peritoneal spraying with local 
anesthetic (one study, 100 participants), the need for opioid rescue was reduced (risk ratio (RR) 0.51; 95% CI 
0.38 to 0.69). The numerical pain score (0 to10) within the first hour was also reduced (mean difference (MD) -
1.46; 95% CI -2.60 to -0.32). 
Patients with regional analgesia, who had local anesthetic and non-steroidal anti-inflammatory cocktail wound 
infiltration, consumed less morphine (one study, 60 participants; MD -7.40 mg; 95% CI -9.58 to -5.22) compared 
to local anesthetic control. 
Patients who had regional analgesia with abdominal nerves blocked, had decreased opioid consumption (four 
studies, 175 participants; MD -25.80 mg; 95% CI -50.39 to -5.37). 
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For the outcome of visual analogue scale 0 to 10 over 24 hours, no advantage was demonstrated in the single 
study of fifty participants who had their wounds infiltrated with a mixture of local analgesia and narcotics versus 
local analgesia. Addition of ketamine to the local analgesia in patients who had regional analgesia does not confer 
any advantage. 
Authors' conclusions   
Local anaesthetics infiltration, including the peritoneum and abdominal nerve blocks as adjuncts to regional or 
general anaesthesia, are of benefit in caesarean sections, by reducing opioid consumption. Non-steroidal anti-
inflammatory drugs as an adjuvant may confer additional pain relief. 
 
Plain language summary   
Childbirth by operation (caesarean section) is becoming more frequent. Caesarean section requires an 
anaesthesia (pain blocking interventions) - either spinal, spinal epidural, epidural block (pain blocking by injection 
in the spine) or general anaesthesia (making the patient to sleep without feeling the pain).  
Post-operative pain is managed with a combination of an opioid such as morphine or pethidine and other 
analgesics. Such opioids cause sedation and they can be transferred to breast milk, also sedating the newborn 
infant. Childbirth is a deeply emotional experience and involves bonding with the newborn and starting 
breastfeeding. Improvements in pain relief that make the post delivery period more comfortable for the mother are 
important. During the operation, local anaesthetics can be injected to block the nerves before cutting the skin or 
after closing the skin at the end of the operation (abdominal nerve block), or the wound can be irrigated or 
infiltrated with  anaesthetic solution to reduce pain after operation (pre-emptive wound analgesia). 
Twenty trials, that were of predetermined adequate qualities and involving 1150 patients, were identified. These 
trials were carried out in both developed and developing countries. In general, local anaesthesia wound infiltration 
was of benefit in patients having a caesarean section requiring regional anaesthetics, because of a reduction in 
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the use of opioid analgesia. Patients undergoing general anaesthesia, who had wound infiltration with local 
anaesthetics and down to the surface of the wound, required lower amounts of opioids in the first 24 hours post-
operation compared to saline control. Those patients who had a general anaesthetic and the abdominal wall 
nerves blocked had reduced pain scores within the first 24 hours post-operative. 
Patients who had regional anaesthesia and abdominal nerves blocked, also benefited by decrease in opioid 
requirements. Non-steroidal anti-inflammatory drugs (another form of pain relieving medication) provided 
additional pain relief but with more side effects of generalised body itching. The commonly used local anaesthetic 
agents do have side effects - but these are very rare - ranging from allergy to blood vessels, heart and nervous 
side effects.  There was no report of side effects in infants following local anaesthetic infiltration, but the number 
of patients studied was small. The longer theatre time and cost of the local anaesthetic may be offset by less use 
of pain relieving medications after operation. The effect on the development of chronic pelvic pain should be an 
important area of research in the nearest future. 
 
Background   
Caesarean section delivery is becoming more frequent and is one of the most common major operative 
procedures performed worldwide. Widely varying rates of caesarean sections have been quoted from around the 
world. What is certain is that the rate is increasing. In the United States, a caesarean section rate of 26% for all 
births is reported (CDC 2002). It approaches 25% in Canada and is over 20% in England, Wales and Northern 
Ireland (RCOG 2001). In the private health sector in South Africa, one study noted a much higher figure of 57% 
(Tshibangu, 2002). 
Childbirth is a profound emotional experience for a woman and her family. The mother needs to bond with the 
newborn baby as early as possible. The need for early breastfeeding cannot be over-emphasised. Breastfeeding 
is economical, and it is emotionally satisfying to most women. It helps to contract the uterus and accelerates the 
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process of uterine involution in the postpartum period. It promotes mother-infant bonding. It may also protect the 
breast against future cancer (Pernoll, 1991). Any form of intervention that leads to improvement in pain relief can 
positively impact on early breastfeeding. Prompt and adequate post-operative pain relief is therefore an important 
component of caesarean delivery that can make the immediate post-delivery period less discomforting and more 
emotionally gratifying. Management of post-operative pain after a caesarean section has mostly involved the use 
of opioids in combination with other forms of analgesics (multimodal analgesic regimen). Any intervention that can 
alleviate post-operative pain is worthy of investigation, and any procedural intervention that is performed while 
carrying out the surgery needs to be adequately assessed before being widely accepted as the norm. 
Caesarean section is done under spinal anaesthesia, spinal epidural, epidural block or general anaesthesia. Intra-
operatively, short- or medium-acting sedatives, narcotics and local anaesthesia have been employed as an 
adjunct to anaesthesia or to alleviate post-operative pain. Local anesthetics cause reversible blockade of impulse 
propagation along the nerve fibers by preventing the influx of sodium ions through the cell membrane of the nerve 
fibers. Several studies have given reports on pre-emptive local anesthetics (local anesthetic given during 
operation to prevent or reduce pain after operation) to relieve post-operative pain, ranging from being beneficial 
(Ganta, 1994; Johansson, 1997) to no benefit (Adams, 1991; Friedman, 2001). 
The timing of local anesthetic administration may either be by pre- or post-incision abdominal nerve block - local 
anesthetics injected to block the nerves before cutting the skin at the beginning of operation, or after closing the 
skin at the end of operation (Trotter, 1991) - or pre- or post-incision abdominal wound infiltration (Ganta, 1994; 
Kumar, 1999). It may also be by continuous wound irrigation (Givens, 2002). 
Several local anesthetic agents have been used as pre-emptive analgesia (xylocaine, bupivacaine or ropivacaine 
at different concentrations), either on their own, or in combination with opioids. The commonly used local 
anesthetic agents have side effects, even though very rare, ranging from allergy to cardiovascular and central 
nervous system effects. The effects on wound healing may be beneficial as the local anesthetic agent is often 
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combined with vasoconstrictors. Ropivacaine on its own has an intrinsic vasoconstricting property. Local 
anesthetics eventually get absorbed systemically and secreted in breast milk but side effects on breastfed babies 
have not yet been documented. This is in sharp contrast to morphine or pethidine, both of which have a significant 
transfer to breast milk and may have a sedative effect on the baby (Pernoll, 1991). 
It is also important to consider the additional cost implication of this intervention. Should it prove to be of benefit, 
the actual cost of the local anesthetic and the added time needed to carry out the procedure may be justified, 
considering the long-term sequel of pain and immobility in the immediate post-caesarean section period. 
 
Objectives   
To assess the effects of local anesthetic agent wound infiltration/irrigation and/or abdominal nerve blocks on post-
caesarean section pain relief; to assess the effect on the mother's physical, social and mental well being; and to 
assess the effect on the mother's ability to meet the physical, psychological and nutritional needs of the baby. 
 
Methods  
Criteria for considering studies for this review:   
Types of studies   
Prospective randomised controlled trials. 
Types of participants   
Women undergoing caesarean section, either electively or as an emergency. 
Types of interventions   
1. Local anesthetic agent wound infiltration versus placebo/no infiltration 
2. Ilioinguinal/iliohypogastric nerve block versus placebo/no treatment 
3. Local anesthetic agent versus other methods of pain relief 
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4. Comparison of different local anesthetic agent techniques 
Types of outcome measures   
1. Post-operative pain scores 
2. Post-operative analgesia requirement 
3. Time to first rescue analgesia 
4. Post-operative fever 
5. Duration of caesarean section 
6. Onset of mobilisation 
7. Onset of breastfeeding 
8. Duration of any breastfeeding 
9. Duration of exclusive breastfeeding 
10. Minor side effects of the local anesthetic 
11. Major side effects, e.g. central nervous system or cardiovascular 
12. Duration of hospital stay 
13. Post-operative wound infection 
14. Women's pain relief satisfaction 
15. Overall satisfaction 
16. Occurrence of postnatal depression or neurotic/psychotic disorders 
17. Chronic pelvic pain 
18. Caregiver satisfaction 
19. Cost 
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Search methods for identification of studies   
Electronic searches   
We searched the Cochrane Pregnancy and Childbirth Group‘s Trials Register by contacting the Trials Search Co-
coordinator (April 2009). The Cochrane Pregnancy and Childbirth Group‘s Trials Register is maintained by the 
Trials Search Co-coordinator and contains trials identified from: 
1. Quarterly searches of the Cochrane Central Register of Controlled Trials (CENTRAL); 
2.  Weekly searches of MEDLINE; 
3.  Hand searches of 30 journals and the proceedings of major conferences; 
4.  Weekly current awareness alerts for a further 44 journals plus monthly BioMed Central email alerts. 
Details of the search strategies for CENTRAL and MEDLINE, the list of hand searched journals and conference 
proceedings, and the list of journals reviewed via the current awareness service, can be found in the ‗Specialised 
Register‘ section within the editorial information about the Cochrane Pregnancy and Childbirth Group. 
Trials identified through the searching activities described above are each assigned to a review topic (or topics). 
The Trials Search Co-coordinator searches the register for each review using the topic list rather than keywords.  
We did not apply any language restrictions. 
 
Data collection and analysis   
Selection of studies 
We assessed for inclusion, all potential studies we identified as a result of the search strategy. 
 
Data extraction and management 
We designed a form to extract data. One review author extracted the data (Student-AAB) using the agreed form 
and the second author (supervisor GJH) cross-checked. No major discrepancies were identified. An independent 
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Cochrane reviewer assess for inclusion, the trial published by the Student. Details are in the appendix section. 
We used the Review Manager software (RevMan 2008) to double enter all the data.  
 
Assessment of methodological quality of included studies 
We assessed the validity of each study using the criteria outlined in the Cochrane Handbook for Systematic 
Reviews of Interventions (Higgins, 2008). We described methods used for generation of the randomisation 
sequence for each trial. 
(1) Sequence generation (checking for possible selection bias) 
We have described for each individual study the method used to generate allocation sequence in sufficient detail 
to allow an assessment of whether it should produce comparable groups. We have assessed the method as: 
 Adequate (any truly random process, e.g., random number table; computer random number generator); 
 Inadequate (any non-random process, e.g., odd or even date of birth; hospital or clinic record number) 
 Unclear. 
(2) Allocation concealment (checking for possible selection bias) 
We described for each included study the method used to conceal the allocation sequence in sufficient detail and 
determined whether intervention allocation could have been foreseen in advance of, or during recruitment, or 
changed after assignment. We assessed the methods as: 
 Adequate (e.g., telephone or central randomization; consecutively numbered sealed opaque envelopes); 
 Inadequate (open random allocation; unsealed or non-opaque envelopes; alternation; date of birth); 
 Unclear. 
(3) Blinding (checking for possible performance bias) 
We have described for each included study the methods used, if any, to blind study participants and personnel, 
from knowledge of which intervention a participant received. We have judged studies to be at low risk of bias if 
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they were blinded, or if we judged that the lack of blinding could not have affected the results. We have assessed 
blinding separately for different outcomes or classes of outcomes. We have assessed the methods as: 
 Adequate, inadequate, or unclear for participants; 
 Adequate, inadequate, or unclear for personnel; 
 Adequate, inadequate, or unclear for outcome assessors. 
(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol 
deviations) 
We have described for each included study, and for each outcome or class of outcomes, the completeness of 
data including attrition and exclusions from the analysis. We assessed methods as: 
 Adequate; 
 Inadequate; 
 Unclear. 
(5) Selective reporting bias 
We have assessed the methods as: 
 Adequate (where it is clear that all of the study‘s pre-specified outcomes and all expected outcomes of 
interest to the review have been reported); 
 Inadequate (where not all the study‘s pre-specified outcomes have been reported; one or more reported 
primary outcomes were not pre-specified; outcomes of interest are reported incompletely and so cannot 
be used; study fails to include results of a key outcome that would have been expected to have been 
reported); 
 Unclear. 
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Measures of treatment effect 
We carried out statistical analysis using the Review Manager software (RevMan, 2008). We used fixed-effect 
meta-analysis for combining data in the absence of significant heterogeneity if trials were sufficiently similar. 
When heterogeneity was found, we used random-effects analysis. 
Dichotomous data 
For dichotomous data, we presented results as summary risk ratio with 95% confidence intervals. 
Continuous data 
For continuous data, we used the mean difference if outcomes were measured in the same way between trials. 
We used the standardised mean difference to combine trials that measured the same outcome, but used different 
methods. 
Dealing with missing data 
We analysed data on all participants with available data in the group to which they were allocated, regardless of 
whether or not they received the allocated intervention. 
Assessment of heterogeneity 
We applied tests of heterogeneity between trials, if appropriate, using the I2 statistic. In the event of significant 
heterogeneity, we used a random-effects meta-analysis as an overall summary if we determined that this was 
appropriate. 
Subgroup analyses 
We performed sub-group analysis for patients who had general anaesthesia versus regional analgesia. 
Sensitivity analyses 
We excluded studies of poor quality (those rating B, C or D) in order to assess for any substantive difference to 
the overall result. 
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Results   
Description of studies   
We identified 40 studies. Twenty studies, involving 1150 patients, carried out in both developed and developing 
countries spanning almost two decades, met the inclusion criteria - see Characteristics of included studies table 
for details of the individual studies. For details of the 12 excluded studies, see Characteristics of excluded studies. 
There are four ongoing studies (Carvel, 2007; Griffiths, 2005; Holmstrom, 2006; Wolfson, 2007) and four studies 
are awaiting classification (Bensghir, 2008; Kanchanakitsakul, 1999; Kuppuvelumani, 1992; Rackelboom, 2008). 
 
Risk of bias in included studies   
See the results of the assessment of trial quality. 
 
Effects of interventions   
1. Wound infiltration with local anesthetics only versus control 
Patients who had caesarean sections performed under regional anaesthesia and had wound infiltration had a 
decrease in morphine consumption at 24 hours (three studies, 126 participants; standardised mean difference 
(SMD) -1.70mg; 95% confidence interval (CI) -2.75, -0.94) compared to placebo. There was no difference in 
visual analogue pain. 
In one study of patients under general anesthetic, who had the caesarean section wound infiltrated and peritoneal 
spraying with local anesthetic (one study, 100 participants), the need for opioid rescue was reduced (risk ratio 
(RR) 0.51; 95% CI 0.38 to 0.69). Numerical pain score (0 to 10) within the first hour was reduced (MD -1.46; 95% 
CI -2.60 to -0.32). 
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The amount of oral Tramadol/acetaminophen (375 mg paracetamol + 150 mg tramadol) consumed was reduced 
in the local anesthetic group compared to saline control (MD -2.35 mg; 95% CI -3.62 to -1.08). 
2. Local anesthetics versus local anesthetic and non-steroidal anti-inflammatory drugs (NSAID) mixture 
Patients operated under regional anaesthesia and who had a local anesthetic and NSAID cocktail wound 
infiltration consumed less morphine in the first 18 hours (one study, 60 participants; MD -7.40 mg; 95% CI -9.58 to 
-5.22) compared to local anesthetic only control. There was no difference in the occurrence of vomiting or 
reduction in antiemetic usage (RR 1.40 mg; 95% CI 0.90 to 2.16). 
3. Anterior abdominal nerves block with local anesthetic versus control 
Patients who had regional anaesthesia and had the abdominal nerves blocked had decreased opioid 
consumption (four studies, 175 participants; MD -25.80 mg; 95% CI -50.39 to -5.37) but no difference in visual 
analogue pain score (0 to 10) (one study, 59 participants; RR -5.00; 95% CI -11.27 to -1.21). 
4. Local anesthetics versus local anesthetics + narcotics 
No advantage, in the visual analogue scale over 24 hours, was demonstrated in the single study of 50 participants 
who had wound infiltration with a mixture of local anesthetic and narcotics versus local anesthetics. 
5. Local anesthetics versus local anesthetics + ketamine 
Addition of ketamine to the local anaesthetic in patients, who had regional anaesthesia, does not confer any 
advantage neither in terms of narcotic consumption nor patient satisfaction. (One study and fifty participants). 
 
Discussion   
Minimising pain after caesarean section is best achieved using a multimodal approach. Local anesthetics from 
lidocaine to the more recent ropivacaine have been used as pre-emptive analgesics since the 1980s. Clinical 
trials were only published in the early 1990s. Local anesthetics has been used with patients undergoing general 
anesthetic, regional anaesthesia and rarely purely under local anesthetic when other anaesthesia was unavailable 
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or unsafe. Various routes of administration have been tested such as subcutaneous wound infiltration, infiltration 
through all layers of the abdomen, continuous wound instillation or iliohypogastric/ilioinguinal nerve blocks. 
Ultrasound guided nerve blocks may soon be explored. Local anesthetic has been used either alone or in 
combination with non-steroidal anti-inflammatory agents or ketamine. 
This review showed that patients undergoing regional analgesia who had local anesthetic infiltration or abdominal 
nerve block had reduction in the use of post-operative opioids. Addition of non-steroidal anti-inflammatory drugs 
to the local anesthetic for caesarean section wound infiltration conferred additional advantage. This may be 
explained because of the addition of another type of analgesic with a different mode of action. Opioid 
consumption may not be the optimal method of pain assessment because of being influenced by the patients' fear 
of dependency, but this effect is balanced by the randomisation process. Significant results must be regarded with 
caution because of testing at multiple times and the results are mostly based on single trials involving few 
patients. 
None of the trials addressed the effect on chronic pelvic pain and cost implications. 
 
Authors’ conclusions 
Implications for practice   
In general, local anaesthesia is of benefit in patients having a caesarean section by reduction in opioid 
consumption. It can be recommended, with consideration to affordability, as part of the multimodal approach to 
pain relief. 
Implications for research   
A cost-benefit analysis is needed. There will be more theatre time spent and cost of the local anesthetic and 
accessories. This may be offset by less use of post-operative analgesia. A pharmacokinetic study of local 
anesthetic absorption following wound and peritoneal infiltration is necessary. Ultrasound guided direct block of 
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the anterior abdominal wall nerves during caesarean sections should be explored. An important research agenda 
will also be the effect of the intervention on chronic pelvic pain. 
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Characteristics of studies   
Characteristics of included studies   
Bamigboye 2008   
Methods Randomised double-blind, placebo-controlled trial. 
Participants 100 consented patients undergoing elective caesarean section. 
Interventions 50 patients received 225 mg ropivacaine if 64 kg or more and 3 mg/kg 
if less. The control received equivalent volume of saline. All layers of 
the anterior abdominal incision were infiltrated including the 
peritoneum. Postoperatively, the women had pethidine, diclofenac 
injection and Tramadol/acetaminophen. 
Outcomes Need for rescue pethidine within one hour of caesarean section and 
occurrence of severe pain at the end of the first hour. Other outcomes 
were numerical pain rating scores, amount of other analgesics 
consumed and side effects such as nausea, vomiting and pruritus. 
Notes An independent reviewer, T Lawrie, assessed the trial and was judged 
to be eligible. 
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 Computer-generated random sequence. 
Allocation concealment? 
 Adequate by drawing ropivacaine or saline from a 
No
Yes
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galipot prepared by theatre nursing manager. 
Blinding? 
 
Sealed envelope, surgeon, anesthetist, midwife 
blinded to allocation 
Incomplete outcome data addressed? 
 
Few outcomes omitted especially at night when 
patients requested not to be disturbed. It balanced out 
in both arms of allocation. 
Free of selective reporting? 
 No evidence of selective reporting 
Free of other bias? 
 No known bias recognised. 
 
Bell 2002   
Methods Randomised double-blind placebo-controlled trial. 
Participants 59 patients for caesarean section randomised to receive nerve block 
or saline placebo. 
Interventions 31 patients had ilioinguinal-iliohypogastric nerve block with 0.5% 
bupivacaine with adrenaline and 28 had saline placebo. 
Outcomes Post-operative morphine use and visual analogue pain scores. 
Notes  
Risk of bias table   
Item Judgment Description 
Yes
Yes
Yes
Yes
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Adequate sequence generation? 
 Computer-generated block randomisation. 
Allocation concealment? 
 A - Adequate. 
Blinding? 
 Double blinded 
Incomplete outcome data addressed? 
 No incomplete data 
Free of selective reporting? 
 No evidence of selective reporting 
Free of other bias? 
 No recognised bias 
 
Caulry 2003   
Methods Randomised placebo-controlled trial. 
Participants 30 patients undergoing spinal anaesthesia randomised into 10 each of 
saline, ropivacaine and diclofenac. 
Interventions Wound irrigation in each group. 
Outcomes Visual analogue pain scores and use of morphine. 
Notes  
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 
Generated random sequence, but not stated how this 
was achieved. 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
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Allocation concealment? 
 Not stated 
Blinding? 
 Not stated 
Incomplete outcome data addressed? 
 No evidence of incomplete outcome 
Free of selective reporting? 
 No evidence of selective reporting 
Free of other bias? 
 No noted bias 
 
Chen 1990  
 Methods Randomised clinical trial. 
Participants 36 patients were randomised into 12 no treatment, 12 plain Marcaine 
and 12 Marcaine with adrenaline. 
Interventions Ilioinguinal nerve block after caesarean section. 
Outcomes Pain, times of pethidine injection, the first time and dosage of 
pethidine injection, postpartum hemorrhage and uterine atony. 
Notes  
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 
Randomised trial but method of generation of 
allocation sequence unclear 
Unclear
Unclear
Unclear
Yes
Yes
Unclear
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Allocation concealment? 
 Not stated 
Blinding? 
 Not stated 
Incomplete outcome data addressed? 
 There were no drop outs 
Free of selective reporting? 
 No selective reporting 
Free of other bias? 
 
Chinese Mandarin language translated by 
professionals. 
 
Ganta 1994   
Methods Randomised single-blind placebo-controlled trial. 
Participants 62 patients having elective caesarean section under general 
anaesthesia. 
Interventions 21 patients had bilateral ilioinguinal nerve block with 0.5% 
bupivacaine, 20 patients had wound infiltration with 0.5% bupivacaine 
and 21 received no local anaesthetic. 
Outcomes Visual analogue scale pain scores in first 24 hours and mean 
morphine consumption in 24 hours. 
Notes  
Risk of bias table   
Item Judgment Description 
Unclear
Unclear
Yes
Yes
Yes
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Adequate sequence generation? 
 Method of generation not stated. 
Allocation concealment? 
 Not concealed 
Blinding? 
 Not blinded 
Incomplete outcome data addressed? 
 Data complete 
Free of selective reporting? 
 No selective reporting 
Free of other bias? 
 Free 
 
Givens 2002   
Methods Randomised double-blind placebo-controlled trial. 
Participants 36 patients for planned caesarean section. 
Interventions 20 patients with wound irrigation with 0.25% bupivacaine versus 16 
women with normal saline solution irrigation. 
Outcomes Post-operative morphine use and visual analogue pain scores. 
Notes  
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 Computer-generated randomisation schedule. 
Allocation concealment? 
 Sealed packets that contained group assignments. 
Unclear
No
No
Yes
Yes
Yes
Yes
Yes
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Blinding? 
 
Adequately blinded to surgeons, patients and data 
recorder. 
Incomplete outcome data addressed? 
 Complete outcome data. 
Free of selective reporting? 
 No evidence of selective reporting. 
Free of other bias? 
 No evidence of other bias. 
 
Kumar 1999   
Methods Randomised-controlled trial. 
Participants 50 ASA I and II patients for elective caesarean section. 
Interventions 24 patients received pre-incisional 40 ml of 0.5% bupivacaine versus 
26 who received 40 ml of bupivacaine and 2 mg morphine mixture. 
Outcomes Visual analogue pain scores at different hours in the first 24 hours and 
side effects of vomiting, nausea and pruritus. 
Notes  
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 
Randomised trial but method of generation of 
sequence not stated. 
Allocation concealment? 
 Method of concealment not stated. 
Yes
Yes
Yes
Yes
Unclear
Unclear
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Blinding? 
 Trial stated to be blinded. 
Incomplete outcome data addressed? 
 Outcome data was complete. 
Free of selective reporting? 
 No selective reporting noted. 
Free of other bias? 
 No other bias noted. 
 
Kuppuvelamini 1992   
Methods Randomised controlled trial. 
Participants 60 patients undergoing caesarean section under general anaesthesia. 
Interventions A mixture of 0.5% bupivacaine with adrenaline with 1% xylocaine was 
injected to block the ilioinguinal/iliohypogastric in 30 patients versus 
control in another 30 patients who did not receive abdominal nerve 
block. 
Outcomes Time to breastfeeding, total pethidine requirement over 24 hours and 
duration of action of the block. 
Notes  
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 
Random sequence but method of generation not 
stated. 
Unclear
Yes
Yes
Yes
Unclear
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Allocation concealment? 
 No concealment. 
Blinding? 
 Control arm did not receive placebo or control block. 
Incomplete outcome data addressed? 
 Data was complete. 
Free of selective reporting? 
 No evidence of selective reporting. 
Free of other bias? 
 No other bias noted. 
 
Lacrosse 2004   
Methods Prospective randomised trial. 
Participants 55 healthy parturients for caesarean section under spinal anaesthesia. 
Interventions 19 patients had wound irrigation with 300mg of diclofenac for 48hrs, 
18 patients had ropivacaine 0.2% and 18 women had saline control. 
Outcomes Local ropivacaine wound infiltration is superior to diclofenac only in 
the first 24 hours but diclofenac has a better opioid sparing effect. 
Notes Lacrosse 2004 looked at delayed benefit of diclofenac for residual 
pain at 1-6 months. 
 
Risk of bias table 
 Item Judgment Description 
Unclear
No
Yes
Yes
Yes
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Adequate sequence generation? 
 
Random allocation but method of generation not 
stated. 
Allocation concealment? 
 Not stated. 
Blinding? 
 Not stated. 
Incomplete outcome data addressed? 
 Data complete. 
Free of selective reporting? 
 No selective reporting noted. 
Free of other bias? 
 Free of bias. 
 
Lavand'homme 2007   
Methods Randomised double-blind placebo-controlled trial. 
Participants 90 patients randomly allocated to receive saline, diclofenac or 0.2% 
ropivacaine. 30 in each group. 
Interventions Continuous wound infiltration of the allocated interventions. 
Outcomes Post-operative morphine consumption, parietal and visceral visual 
analogue pain scores. 
Notes  
Risk of bias table   
Item Judgment Description 
Unclear
Unclear
Unclear
Yes
Yes
Yes
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Adequate sequence generation? 
 Computer-generated random sequence. 
Allocation concealment? 
 Adequate. 
Blinding? 
 
Adequate; the patient, the peri-operative management 
team and the data collectors were all blinded. 
Incomplete outcome data addressed? 
 Data was complete. 
Free of selective reporting? 
 No selective reporting. 
Free of other bias? 
 Free of other bias. 
 
Marbaix 2004   
Methods Randomised prospective trial. 
Participants 55 healthy parturients for elective caesarean section under spinal 
anaesthesia. 
Interventions 19 patients had wound irrigation with 300 mg of diclofenac for 48 
hours, 18 patients had ropivacaine 0.2%, 18 women had saline 
control. 
Outcomes Visual analogue pain scores and morphine consumption. 
Notes Continuation of the same trial presented authored by Lacrosse 2004. 
Risk of bias table   
Item Judgment Description 
Yes
Yes
Yes
Yes
Yes
Yes
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Adequate sequence generation? 
 Unstated. 
Allocation concealment? 
 Unstated. 
Blinding? 
 Unstated. 
Incomplete outcome data addressed? 
 Complete data. 
Free of selective reporting? 
 Free. 
Free of other bias? 
 Free. 
 
McDonnell 2008   
Methods Randomised controlled trial. 
Participants 50 patients undergoing caesarean sections under spinal anaesthesia. 
Interventions 1.5 mg/kg ropivacaine, per side injection into the transversus 
abdominis plane (TAP) versus saline TAP block. 
Outcomes Morphine requirement, prolonged and superior analgesia up to 36 
hours postoperative. 
Notes TAP block targets sensory innervations of anterior abdominal wall 
before leaving the triangle of Petit. 
Risk of bias table   
Item Judgment Description 
Unclear
Unclear
Unclear
Yes
Yes
Yes
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Adequate sequence generation? 
 Random number table. 
Allocation concealment? 
 Opaque sealed envelopes. 
Blinding? 
 
Patients, anesthesiologists, surgeon and 
postoperative team were all blinded. 
Incomplete outcome data addressed? 
 Complete. 
Free of selective reporting? 
 Free. 
Free of other bias? 
 Free of bias. 
 
Mecklem 1995   
Methods Randomised double-blind placebo-controlled trial. 
Participants 79 patients undergoing caesarean section under spinal analgesia. 
Interventions Patients were allocated to receive either saline or 0.25% bupivacaine. 
Outcomes Visual analogue pain scores, morphine consumption and 
gastrointestinal side effect. 
Notes  
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 Tables of random numbers. 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
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Allocation concealment? 
 
Adequate by using coded ampoules of bupivacaine 
and saline. 
Blinding? 
 Coded ampoules of saline or Marcaine. 
Incomplete outcome data addressed? 
 Complete outcome data. 
Free of selective reporting? 
 Free. 
Free of other bias? 
 No other bias. 
 
Pavy 1994   
Methods Randomised trial. 
Participants 40 patients for elective caesarean section. 
Interventions Group A - 20 patients received 0.5% bupivacaine, group B - 20 
patients received saline. 
Outcomes Pain scores, pruritus and nausea. 
Notes  
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 Random table was used. 
Allocation concealment? 
 Adequate. 
Yes
Yes
Yes
Yes
Yes
Yes
Yes
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Blinding? 
 To all parties. 
Incomplete outcome data addressed? 
 Complete data. 
Free of selective reporting? 
 Free. 
Free of other bias? 
 Free of other bias. 
 
Pirbudak 2004   
Methods Randomised double blind. 
Participants 60 patients undergoing caesarean delivery under spinal anaesthesia. 
Interventions Group 1 received 40 ml of 0.25% bupivacaine + 100 mg tramadol + 20 
mg tenoxicam. Group 2 received normal saline. 
Outcomes Reduction in post-operative analgesic use and prolongation of 
analgesic requirement time. 
Notes  
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 
Randomised trial but method of randomisation not 
stated. 
Allocation concealment? 
 Not described. 
Yes
Yes
Yes
Yes
Unclear
Unclear
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Blinding? 
 Method of achieving blinding not described. 
Incomplete outcome data addressed? 
 Data complete. 
Free of selective reporting? 
 No evidence of selective reporting. 
Free of other bias? 
 Free of other bias. 
 
Rosaeg 1997   
Methods Randomised controlled trial. 
Participants 40 patients for elective caesarean sections under spinal analgesia. 
Interventions Group 1: experimental patients received intrathecal morphine, 
incisional bupivacaine and ibuprofen and acetaminophen. Group 2 
received intravenous morphine weaned to acetaminophen and 
codeine. Both groups received 7.5mg/ml solution bupivacaine spinal 
analgesia. 
Outcomes Visual analogue pain scores at rest and at mobilisation. Time to first 
walking, eating, bowel movement and voiding. 
Notes  
 
Risk of bias table   
Item Judgment Description 
Unclear
Yes
Yes
Yes
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Adequate sequence generation? 
 Computer-generated set of random numbers. 
Allocation concealment? 
 Adequate concealment. 
Blinding? 
 Blinded. 
Incomplete outcome data addressed? 
 Data complete. 
Free of selective reporting? 
 No evidence of selective reporting. 
Free of other bias? 
 Free. 
 
Solak 1999   
Methods Randomised trial. 
Participants 30 ASA patients for elective caesarean sections. 
Interventions Patients randomised to receive either 20 ml of 0.5%bupivacaine or 
saline. 
Outcomes Visual analogue pain scale scores, analgesic requirement and cortisol 
level. 
Notes No formal interpretation from Turkish available. 
Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 Randomised trial, method unknown. 
Yes
Yes
Yes
Yes
Yes
Yes
Unclear
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Allocation concealment? 
 Concealed. 
Blinding? 
 Blinded. 
Incomplete outcome data addressed? 
 Data complete. 
Free of selective reporting? 
 No selective reporting. 
Free of other bias? 
 Language barrier. 
 
Trotter 1991   
Methods Randomised double-blind trial. 
Participants 28 patients for elective caesarean section. 
Interventions Group B received 0.5% bupivacaine and the control group C received 
saline. 
Outcomes Morphine consumption, pain scores, sedation level and nausea. 
Notes  
Risk of bias table  
Item Judgment Description 
Adequate sequence generation? 
 Random sequence, method of generation unknown. 
Allocation concealment? 
 Adequately concealed. 
Blinding? 
 Solutions supplied in numbered vials. 
Yes
Yes
Yes
Yes
No
Yes
Yes
Yes
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Incomplete outcome data addressed? 
 Complete. 
Free of selective reporting? 
 Free. 
Free of other bias? 
 Free of any other bias. 
 
Zohar 2002   
Methods Prospective randomised double-blind study that assessed the 
analgesic efficacy of ketamine when administered as an adjuvant to 
bupivacaine for patient controlled wound instillation following 
caesarean section. 
Participants 50 term parturients undergoing caesarean section under spinal 
anaesthesia. 
Interventions A multi-holed device is placed in the wound and connected to a 
patient controlled pump. Group 1 had bupivacaine and Group 2 
combined with ketamine. 
Outcomes Visual analogue scale for pain, rescue morphine, patient satisfaction. 
Notes  
 
Risk of bias table   
Item Judgment Description 
Yes
Yes
Yes
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Adequate sequence generation? 
 Method of randomisation not stated. 
Allocation concealment? 
 Method not stated 
Blinding? 
 
Double blinded trial even though how it was achieved 
was not described. 
Incomplete outcome data addressed? 
 Complete. 
Free of selective reporting? 
 Free. 
Free of other bias? 
 Free. 
 
Zohar 2006   
Methods Prospective, randomised, double-blind, placebo-controlled trial. 
Participants 90 parturients (ASA1 & 2) undergoing elective caesarean section. 
Interventions Group 1: 30 patients had wound instillation via a patient-controlled 
analgesic infusion pump of 0.25% bupivacaine and 75 mg intravenous 
diclofenac. Group 2 received only bupivacaine instillation. Group 3 
received only diclofenac infusion. 30 patients in each group. 
Outcomes Rescue analgesic required, visual analogue pain scale, nausea and 
patient satisfaction. 
Notes  
 
Unclear
Unclear
Unclear
Yes
Yes
Yes
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Risk of bias table   
Item Judgment Description 
Adequate sequence generation? 
 Computer-generated randomisation schedule. 
Allocation concealment? 
 Adequate. 
Blinding? 
 Adequately blinded. 
Incomplete outcome data addressed? 
 Data complete. 
Free of selective reporting? 
 Free. 
Free of other bias? 
 Free. 
 
Characteristics of excluded studies   
Bisson 1991   
Reason for exclusion Inadequate published data. Only pre-entry characteristics of the study 
populations were given. No table or data of outcome was depicted or 
tabulated. The conclusion of the study is that of no significant 
difference in the visual pain rating scale and the amount of analgesic 
requirement in patients who had bupivacaine wound infiltration under 
general anaesthesia versus placebo. 
 
Bunting 1988   
Yes
Yes
Yes
Yes
Yes
Yes
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Reason for exclusion Inadequate data to include in the meta-analysis. However, the study 
showed longer time to require rescue analgesic and reduce pain 
scores in the nerve block group. There was no side effect noted in 
both groups. 
 
Christie 1993   
Reason for exclusion Inadequate data to include in the meta-analysis and hyperalgesia as 
an outcome measure was not part of the original protocol for this 
review. 
 
Farrugia 1995   
Reason for exclusion Inadequate data to include in the meta-analysis. However, the study 
showed that patients who had nerve block required less rescue 
opioids compared to wound infiltration. 
 
Foster 1983   
Reason for exclusion No randomisation, consecutive patients were allocated. Inadequate 
data for analysis. 
 
Huffnagle 1996   
Reason for exclusion Inadequate data to include in the meta-analysis. However, the study 
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showed that women who had pre-incision abdominal nerve block had 
better pain control. 
 
Lipscomb 2002   
Reason for exclusion Inadequate data for inclusion into the meta-analysis. However, the 
study demonstrated that continuous infusion of 0.25% bupivacaine 
into caesarean section wound reduces postoperative narcotic use. 
 
Momani 2001   
Reason for exclusion Data not adequate for statistical analysis. However, the outcome of 
trial of bupivacaine 0.25% caesarean section wound infiltration 
showed reduction in postoperative analgesic requirement. 
 
Raffo 1999   
Reason for exclusion Inadequate data to include in the meta-analysis. However, the study 
showed that pre-incision local anaesthesia infiltration does not 
improve post-operative analgesia in women who underwent 
spinal/epidural. 
 
Ranta 2004   
Reason for exclusion Inadequate data to include in the meta-analysis. However, the study 
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showed that local wound irrigation for pain relief was comparable in 
efficacy to epidural analgesia. 
 
Schultz 2001   
Reason for exclusion Inadequate data excludes this study. 
 
Thiry 2006   
Reason for exclusion A randomised trial of parietal infiltration of ropivacaine versus saline 
control. No information on data but trial concluded reduction in 
postoperative narcotic usage. 
 
Characteristics of ongoing studies   
Carvalho 2007   
Study name Efficacy of transversus abdominis plane block for post caesarean 
delivery analgesia. 
Methods Randomised trial. 
Participants Women for caesarean delivery. 
Interventions Patients will be assigned to receive 0.375% ropivacaine TAP block or 
a placebo. 
Outcomes Pain scores, opioid consumption. 
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Starting date December 2007. 
Contact information jose.carvalho@uhn.on.ca 
Notes Study is still recruiting. 
 
Griffiths 2005   
Study name A prospective comparison of early postoperative analgesia in 
caesarean section using bilateral ilio-inguinal block and subcutaneous 
morphine. 
Methods Randomised double-blind, parallel assignment, efficacy trial. 
Participants 100 women for caesarean section. 
Interventions 5% bupivacaine. 
Outcomes Decreased postoperative pain and narcotic use. Time to first 
analgesia. 
Starting date 01/02/06. 
Contact information Dr J Griffiths,  box 2002, Ivanhoe east, VIC Australia. 
Notes  
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Holmstrom 2006   
Study name Caesarean delivery and post-operative pain management with local 
anaesthesia. 
Methods Randomised double-blind, parallel assignment, efficacy trial. 
Participants 100 pregnant women with scheduled caesarean delivery. 
Interventions 5% bupivacaine with epinephrine versus control. 
Outcomes Decreased postoperative pain and narcotic use. 
Starting date February 2006. 
Contact information Aron Deutch abdmstrom@hotmail.com 
Notes  
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Wolfson 2007   
Study name A randomised double-blind, placebo controlled trial of ilioinguinal 
iliohypogastric nerve blocks and neuraxial morphine for post 
caesarean analgesia. 
Methods No details yet. 
Participants Women presenting for non-emergency caesarean section. 
Interventions IIIH block in one group versus saline. 
Outcomes Trial is ongoing. 
Starting date Unknown. 
Contact information  
Notes  
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Data and analyses of outcome   
1. Wound infiltration with local anesthetic only versus control   
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
1.1 Total morphine consumption 
as defined by trial author in the 
first 24 hours 
3 126 Std. Mean Difference (IV, 
Random, 95% CI) 
-1.72 [-2.35, -1.09] 
  1.1.1 General anaesthesia 0 0 Std. Mean Difference (IV, 
Random, 95% CI) 
Not estimable 
  1.1.2 Regional anaesthesia 3 126 Std. Mean Difference (IV, 
Random, 95% CI) 
-1.72 [-2.35, -1.09] 
1.2 Total pethidine consumed 24 
hours postdelivery 
1 97 Mean Difference (IV, Fixed, 95% 
CI) 
-44.00 [-108.31, 
20.31] 
  1.2.1 General anaesthesia 1 97 Mean Difference (IV, Fixed, 95% 
CI) 
-44.00 [-108.31, 
20.31] 
  1.2.2 Regional 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
1.3 Visual analogue scale (0-10) 
at 24 hours 
2 56 Mean Difference (IV, Fixed, 95% 
CI) 
-0.39 [-1.72, 0.94] 
  1.3.1 Regional anaesthesia 2 56 Mean Difference (IV, Fixed, 95% 
CI) 
-0.39 [-1.72, 0.94] 
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  1.3.2 General anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
1.4 Numerical pain score (0-10) 
at 1 hour 
1 100 Mean Difference (IV, Fixed, 95% 
CI) 
-1.46 [-2.60, -0.32] 
  1.4.1 General anaesthesia 1 100 Mean Difference (IV, Fixed, 95% 
CI) 
-1.46 [-2.60, -0.32] 
  1.4.2 Regional anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
1.5 Numerical pain score (0-10) 
at 8 hours 
1 100 Mean Difference (IV, Fixed, 95% 
CI) 
-0.58 [-3.29, 2.13] 
  1.5.1 General 1 100 Mean Difference (IV, Fixed, 95% 
CI) 
-0.58 [-3.29, 2.13] 
  1.5.2 Regional 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
1.6 Numerical pain score at 24 
hours 
1 97 Mean Difference (IV, Fixed, 95% 
CI) 
0.19 [-0.67, 1.05] 
  1.6.1 General anaesthesia 1 97 Mean Difference (IV, Fixed, 95% 
CI) 
0.19 [-0.67, 1.05] 
  1.6.2 Regional 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
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1.7 Experience of severe pain 15 
minutes after delivery 
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.09, 0.42] 
  1.7.1 General anaesthesia 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.19 [0.09, 0.42] 
  1.7.2 Regional anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
1.8 Need for pethidine rescue 
within 1 hour of delivery 
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.38, 0.69] 
  1.8.1 General anaesthesia 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.51 [0.38, 0.69] 
  1.8.2 Local anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
1.9 Experience of severe pain 2 
hours post caesarean section 
delivery 
1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.11, 0.88] 
  1.9.1 General anaesthesia 1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.31 [0.11, 0.88] 
  1.9.2 Regional anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
1.10 Experience of severe pain 4 
hours after caesarean delivery 
1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.28, 1.19] 
  1.10.1 General anaesthesia 1 98 Risk Ratio (M-H, Fixed, 95% CI) 0.58 [0.28, 1.19] 
  1.10.2 Regional anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
1.11 Experience of severe pain 
(0-10) 8 hours after caesarean 
delivery 
1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.35, 1.45] 
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  1.11.1 General anaesthesia 1 100 Risk Ratio (M-H, Fixed, 95% CI) 0.71 [0.35, 1.45] 
  1.11.2 Regional anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
1.12 Experience of severe pain 
16 hours post caesarean 
delivery 
1 96 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.11, 1.11] 
  1.12.1 General anaesthesia 1 96 Odds Ratio (M-H, Fixed, 95% CI) 0.35 [0.11, 1.11] 
  1.12.2 Regional anaesthesia 0 0 Odds Ratio (M-H, Fixed, 95% CI) Not estimable 
1.13 Experience of severe pain 
24 hours after caesarean 
delivery 
1 97 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.27, 2.50] 
  1.13.1 General anaesthesia 1 97 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.27, 2.50] 
  1.13.2 Regional anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
1.14 Amount of rescue 
diclofenac (mg) used during 
hospitalisation 
1 95 Mean Difference (IV, Fixed, 95% 
CI) 
-43.79 [-66.95, -
20.63] 
  1.14.1 General anaesthesia 1 95 Mean Difference (IV, Fixed, 95% 
CI) 
-43.79 [-66.95, -
20.63] 
  1.14.2 Regional anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
1.15 Amount of 1 95 Mean Difference (IV, Fixed, 95% -2.35 [-3.62, -1.08] 
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tramadol/acetaminophen (375 
mg paracetamol+150 tramadol) 
tablet used 
CI) 
  1.15.1 General anaesthesia 1 95 Mean Difference (IV, Fixed, 95% 
CI) 
-2.35 [-3.62, -1.08] 
  1.15.2 Regional anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
  
2. Wound infiltration with local anesthetic + non-steroidal anti-inflammatory drugs versus control   
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
2.1 No of attempts to activate 
PCA 
1 60 Mean Difference (IV, Fixed, 95% 
CI) 
-15.00 [-30.22, 0.22] 
  2.1.1 General anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
  2.1.2 Regional anaesthesia 1 60 Mean Difference (IV, Fixed, 95% 
CI) 
-15.00 [-30.22, 0.22] 
2.2 Total morphine (mg) used in 
the first 18 hours 
1 60 Mean Difference (IV, Fixed, 95% 
CI) 
-7.40 [-9.58, -5.22] 
  2.2.1 General anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
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  2.2.2 Regional anaesthesia 1 60 Mean Difference (IV, Fixed, 95% 
CI) 
-7.40 [-9.58, -5.22] 
2.3 Need for antiemetic 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.17, 0.83] 
  2.3.1 General anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
  2.3.2 Regional anaesthesia 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.38 [0.17, 0.83] 
2.4 Patient satisfaction-
good/excellent 
1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [1.02, 1.55] 
  2.4.1 General anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
  2.4.2 Regional anaesthesia 1 60 Risk Ratio (M-H, Fixed, 95% CI) 1.26 [1.02, 1.55] 
2.5 Nausea 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.90, 2.16] 
  2.5.1 General anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
  2.5.2 Regional anaesthesia 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.40 [0.90, 2.16] 
2.6 Pruritus 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.01, 3.23] 
  2.6.1 General anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
  2.6.2 Regional anaesthesia 1 40 Risk Ratio (M-H, Fixed, 95% CI) 1.81 [1.01, 3.23] 
  
3. Abdominal nerve blocks with local anesthetic versus placebo block or no block   
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
3.1 Mean visual analogue scale 2 83 Mean Difference (IV, Fixed, 95% -1.82 [-2.74, -0.90] 
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at 24 hours CI) 
  3.1.1 General anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
  3.1.2 Regional anaesthesia 2 83 Mean Difference (IV, Fixed, 95% 
CI) 
-1.82 [-2.74, -0.90] 
3.2 Postoperative opioid use 
(mg) (as defined by trial authors) 
4 175 Mean Difference (IV, Random, 
95% CI) 
-25.80 [-50.39, -1.21] 
  3.2.1 General anaesthesia 0 0 Mean Difference (IV, Random, 
95% CI) 
Not estimable 
  3.2.2 Regional anaesthesia 4 175 Mean Difference (IV, Random, 
95% CI) 
-25.80 [-50.39, -1.21] 
3.3 No of times mother breast 
fed in 24 hours 
1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.02, 1.61] 
  3.3.1 General anaesthesia 1 60 Risk Ratio (M-H, Fixed, 95% CI) 0.20 [0.02, 1.61] 
  3.3.2 Regional anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
  
4. Wound infiltration with local anesthetic versus local anesthetic + narcotics   
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
4.1 Mean visual analogue score 
at 2 hours 
1 50 Mean Difference (IV, Fixed, 95% 
CI) 
0.69 [-0.08, 1.46] 
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  4.1.1 General anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
  4.1.2 Regional anaesthesia 1 50 Mean Difference (IV, Fixed, 95% 
CI) 
0.69 [-0.08, 1.46] 
4.2 Mean visual analogue score 
at 12 hours 
1 50 Mean Difference (IV, Fixed, 95% 
CI) 
0.18 [-0.59, 0.95] 
  4.2.1 Regional anaesthesia 1 50 Mean Difference (IV, Fixed, 95% 
CI) 
0.18 [-0.59, 0.95] 
  4.2.2 General anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
4.3 Mean visual analogue score 
at 24 hours 
1 50 Mean Difference (IV, Fixed, 95% 
CI) 
-0.15 [-0.92, 0.62] 
  4.3.1 General anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
  4.3.2 Regional anaesthesia 1 50 Mean Difference (IV, Fixed, 95% 
CI) 
-0.15 [-0.92, 0.62] 
  
5. Wound infiltration with local anesthetic versus local anesthetic + ketamine   
Outcome or Subgroup Studies Participants Statistical Method Effect Estimate 
5.1 Total morphine consumed in 1 50 Mean Difference (IV, Fixed, 95% 0.10 [-2.74, 2.94] 
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the first 6 hours CI) 
  5.1.1 General anaesthesia 0 0 Mean Difference (IV, Fixed, 95% 
CI) 
Not estimable 
  5.1.2 Regional anaesthesia 1 50 Mean Difference (IV, Fixed, 95% 
CI) 
0.10 [-2.74, 2.94] 
5.2 Patient satisfaction, 
good/excellent 
1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.42, 3.43] 
  5.2.1 General anaesthesia 1 50 Risk Ratio (M-H, Fixed, 95% CI) 1.20 [0.42, 3.43] 
  5.2.2 Regional anaesthesia 0 0 Risk Ratio (M-H, Fixed, 95% CI) Not estimable 
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Figures 1-17. Forest Plots of Comparisons   
Figure 1 (Analysis 1.1)   
 
Caption 
Forest plot of comparison: 1 Wound infiltration with local anesthetic only versus control, outcome: 1.1 Total 
morphine consumption as defined by trial author in the first 24 hours. 
 
 
 
 
 
 
Study or Subgroup
1.1.1 General anaesthesia
Subtotal (95% CI)
Heterogeneity: Not applicable
Test for overall effect: Not applicable
1.1.2 Regional anaesthesia
Caulry 2003
Givens 2002
Mecklem 1995
Subtotal (95% CI)
Heterogeneity: Tau² = 0.16; Chi² = 4.06, df = 2 (P = 0.13); I² = 51%
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Figure 2 (Analysis 1.2)  
 
 
Caption 
Forest plot of comparison: 1 Wound infiltration with local anesthetic only versus control, outcome: 1.2 Total 
pethidine consumed 24 hours post delivery. 
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Figure 3 (Analysis 1.3)   
 
Caption 
Forest plot of comparison: 1 Wound infiltration with local anesthetic only versus control, outcome: 1.2 Visual 
analogue scale (0-10) at 24 hours. 
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Figure 4 (Analysis 2.2)   
 
Caption 
Forest plot of comparison: 3. Wound infiltration with local anesthetic + non-steroidal anti-inflammatory drugs 
versus control, outcome: 3.2 Total morphine (mg) used in the first 18 hours. 
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Figure 5 (Analysis 2.3)   
 
Caption 
Forest plot of comparison: 3 Wound infiltration with local anesthetic + non-steroidal anti-inflammatory drugs 
versus control, outcome: 3.3 Need for antiemetic. 
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Figure 6 (Analysis 2.4)   
 
Caption 
Forest plot of comparison: 3 Wound infiltration with local anesthetic + non-steroidal anti-inflammatory drugs 
versus control, outcome: 3.4 Patient satisfaction-good/excellent. 
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Figure 7 (Analysis 2.5)   
 
Caption 
Forest plot of comparison: 3 Wound infiltration with local anesthetic + non-steroidal anti-inflammatory drugs 
versus control, outcome: 3.5 Nausea. 
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Figure 8 (Analysis 2.6)   
 
Caption 
Forest plot of comparison: 3 Wound infiltration with local anesthetic + non-steroidal anti-inflammatory drugs 
versus control, outcome: 3.6 Pruritus. 
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Figure 9 (Analysis 3.1)   
 
Caption 
Forest plot of comparison: 4 Abdominal nerve blocks with local anesthetic versus placebo block or no block, 
outcome: 4.1 Mean visual analogue scale at 24 hours. 
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Figure 10 (Analysis 3.2)   
 
Caption 
Forest plot of comparison: 4 Abdominal nerve blocks with local anesthetic versus placebo block or no block, 
outcome: 4.2 Postoperative opioid use (mg) (as defined by trial authors). 
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Figure 11 (Analysis 3.3)   
 
Caption 
Forest plot of comparison: 4 Abdominal nerve blocks with local anesthetic versus placebo block or no block, 
outcome: 4.3 No of times mother breast fed in 24 hours. 
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Figure 12 (Analysis 4.1)   
 
 
Caption 
Forest plot of comparison: 5 Wound infiltration with local anesthetic versus local anesthetic + narcotics, outcome: 
5.1 Mean visual analogue score at 2 hours. 
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Figure 13 (Analysis 4.2)   
 
Caption 
Forest plot of comparison: 5 Wound infiltration with local anesthetic versus local anesthetic + narcotics, outcome: 
5.2 Mean visual analogue score at 12 hours. 
Figure 14 (Analysis 4.3)   
 
Caption 
Forest plot of comparison: 5 Wound infiltration with local anesthetic versus local anesthetic + narcotics, outcome: 
5.3 Mean visual analogue score at 24 hours. 
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Figure 15 (Analysis 5.1)   
 
Caption 
Forest plot of comparison: 6 Wound infiltration with local anesthetic versus local anesthetic + ketamine, outcome: 
6.1 Total morphine consumed in the first 6 hours. 
Figure 16 (Analysis 5.2)   
 
Caption 
Forest plot of comparison: 6 Wound infiltration with local anesthetic versus local anesthetic + ketamine, outcome: 
6.2 Patient satisfaction, good/excellent. 
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Figure 17 (Analysis 2.1)   
 
Caption 
Forest plot of comparison: 3 Wound infiltrations with local anesthetic + non-steroidal anti-inflammatory drugs 
versus control, outcome: 3.1 No of attempts to activate PCA. 
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CHAPTER FIVE 
SUMMARY, IMPLICATION AND RELEVANCE OF THESIS TO OBSTETRICS PRACTICE 
 This thesis provides evidence that local anaesthetic infiltration into the caesarean wound as part of multimodal 
pain strategy, either in general or regional anaesthesia, is of benefit in alleviating post caesarean delivery pain in 
all settings. The serum level of ropivacaine is within safety margins with the dosage used in the trial and there 
were no observable side effects in the mothers studied. This dosage can be extrapolated for use in situations 
where caesarean section needs to be performed under local anaesthetic infiltration only. 
5.1 Relevance to obstetrics settings 
5.1.1. Magnitude of the problem 
On the average around 15% of births worldwide occur by caesarean section. The highest rate (29.2%) is seen in 
Latin America and the Caribbean, the lowest (3.5%) in Africa. Overall, in developed countries, the proportion of 
caesarean births is 21.1% 1. Due to a lack of skill and resources, non-specialist doctors  that administer 
anaesthesia, may be more comfortable performing caesarean sections under general anaesthesia than regional 
(personal experience). To benefit from local anaesthesia for pain relief, a simple reproducible method of wound 
infiltration through all layers of the anterior abdominal wound including the peritoneum, was introduced, which will 
not only block the afferent nociceptive abdominal wall receptors but will also block visceral nerve fibres. With the 
huge numbers of general anaesthetic caesarean deliveries, especially in resource-constrained settings and 
worldwide, local anaesthetic into the wound has a positive role to play. 
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5.1.2. Applicability of the results 
The trials included in the systematic review were conducted in a mix of developed and developing countries. The 
clinical trial was conducted in resource rich settings of a private hospital in a developing country. There is no 
known reason to expect that the results might have been different if all studies had been conducted in under-
resourced hospital settings or in a developed country. Hence, the findings of the systematic review are applicable 
to all settings. The availability of local anaesthetics may play a role in determining applicability of local anaesthetic 
wound infiltration. 
5.2. Implementation of the intervention 
The described method of infiltrating all layers of abdominal wall including spraying/infiltrating the peritoneum in 
caesarean delivery is an innovation. It is reproducible and may not add excessive cost to health care delivery. The 
extra cost may be traded off by the amount of opioid spared with the use of local anaesthetic infiltration. 
5.3. Research agenda 
One of the limitations of this study is the lack of adequate funding to carry out detailed pharmacokinetic trials with 
an adequate sample size. Only ten patients were sampled and nine patients were analysed. A pharmacokinetic 
trial that includes free local anaesthetic serum concentration with an adequate sample size is needed. 
Studies that directly address the role of anaesthetising the peritoneum by comparing subcutaneous wound 
infiltration versus LA to all layers including the peritoneum would be helpful.  
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Pain cannot be quantified hence a cost benefit analysis will be difficult to conduct. However, for purposes of 
budgeting, a cost benefit analysis study that looks at the materials and the additional time spent on local 
anaesthetist infiltration, may be worthy of investigation. 
Further research may investigate the role of ultrasound guided LA infiltration of the ilioinguinal and iliohypogastric 
nerves. In addition, sstudies could investigate whether there is any benefit of LA infiltration of the caesarean 
wound in decreasing chronic pelvic pain. Other areas of interest include pre-incisional infiltration versus post 
delivery infiltration of caesarean section wounds and the investigation of placental LA concentrations following 
pre-incision usage compared to plasma levels during epidural use. 
The clinical and pharmacokinetic trials carried out for this thesis shed a positive light on the feasibility of 
conducting well designed trials in private settings in South Africa. Many will believe that carrying out such a study 
may be met with resistance in the private settings. This was not the case as the patients were well informed, the 
services of caesarean delivery with the Medi-Clinic protocols were followed and the nursing and the anaesthetic 
personnel showed high levels of enthusiasm for the study. The overall environment where the study was carried 
out was welcoming. I recommend that clinical researchers who are in private practise should attempt to conduct 
their studies in such a set-up. 
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APPENDIX 1. 
 
PROTOCOLS FOR CLINICAL AND PHARMACOKINETIC TRIALS 
PATIENT INFORMATION SHEET – PHARMACOKINETIC STUDY OF ROPIVACAINE FOLLOWING 
CAESAREAN SECTION WOUND INFILTRATION. 
 
I, Dr A.A. Bamigboye of the Medi-Clinic Hospital and the University of the Witwatersrand, is conducting a study to 
see whether an injection called ropivacaine, in addition to the normal treatment, reduces the pain that women 
experience on waking up in theatre after the birth of their babies by caesarean section.  
You are kindly invited to participate in the study. If you accept this invitation, the injection will be given at the site 
of the operation to deaden some nerves in the abdomen after your baby has been delivered. This injection works 
for about 4-8 hours which is the time of maximum pain after the operation. Some doctors believe the injection 
reduces pain after the operation. Other doctors believe it does not. One hundred patients have already 
participated in this study to show whether the medication reduces pain or not. We are still awaiting the result for 
these patients.  
Even though one hundred patients already received this injection during their deliveries as part of this research, 
and thousands all over the world had received this injection (ropivacaine) following caesarean section, we are yet 
to measure the amount of ropivacaine in patients who delivered their babies by operation and used this injection 
to reduce pain. The dose of the injection we shall use is within the recommended level that has been used in 
adults.  We need ten patients to agree to have blood samples taken in order to measure the amount of the 
injection, ropivacaine, in their blood at different times. 
To measure the amount of ropivacaine in your blood, while you are sleeping during the operation, the sleep 
doctor (anaesthetist) will insert a very small baby plastic needle through which blood will be taken at different 
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intervals. A teaspoonful (5mls) of blood will be taken from you at 15 minutes, 30 minutes, 60 minutes, 2 hours, 4 
hours, 8 hours 16 hours and 24 hours after the operation. The total amount of blood taken will be less than a third 
of a glass of wine. If this amount of blood is removed in an adult, it does not have any short or long term effect. 
The blood will thereafter be sent for laboratory analysis. 
There may be benefits to participating in this study. The injection that we are studying may decrease the amount 
of pain that you will experience after the operation.  By participating you will be helping to ensure that women, in 
future, get the best treatment for pain control after caesarean section. This injection, ropivacaine, is not new and 
has been well used for many years. The few side effects, including allergies, are known, but rare, and treatment 
of such is available. There is also a possibility of discomfort because of the needle that will be left in your arm for 
24 hours and the injection needle site may swell up and rarely be infected. Should you have any of these 
complaints, we shall act appropriately to correct and treat them.  
 
Any information you provide during the study will be kept confidential.  Your name will not appear on any study 
document and only staff participating in the study will have access to the information you provide.  You are free to 
choose whether or not you wish to participate.  You are also free to withdraw from the study at any time should 
you wish to do so for any reason.  If for any reason you are not eligible for the study, or decide not to participate, 
you will still receive normal care and standard treatment and medications before, during and after birth.  We hope 
you will participate and thank you if you do. 
 
Do you have any questions about the study? 
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CONSENT  
Taking blood for measurement after ropivacaine injection to caesarean section wound to relieve pain. 
I have read (or been read to) the information sheet concerning this study and I understand the content of the 
research.  All my questions and doubts have been answered.  I understand that I can withdraw from the study at 
any time I wish, without giving a reason and this will not affect the normal health care I receive. 
I would like/ would not like to be informed about the results of the trial (circle or cross) 
I… … … … … … … … … … … … … ………………. (Participant‘s full name) agree to take part in this study.   
signature…………………………………………………..…..Date…………………………………….……. 
 
Consenting doctor‘s name ………………………………………………………………..…. 
 
Signature……………………………………………………………………Date…………………………… 
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PHARMACOKINETIC STUDY RECORD SHEET 
 
 
Study No…………………………. 
 
 
Patient‘s Sticker 
 
 
 
 
 
 
Age………………Weight………………….Height………………Parity……………. 
 
 
Time of Ropivacaine injection--------------------------------------- 
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Sample time (min) Time  Signature phlebotomist 
Before injection 
 
  
15min 
 
  
30min 
 
  
60min 
 
  
2hrs 
 
  
4hrs 
 
  
8hrs 
 
  
16hrs 
 
  
24hrs 
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INFORMATION LEAFLET AND INFORMED CONSENT 
 
STUDY TITLE: Pre-emptive ropivacaine wound infiltration and peritoneal spraying for post-operative analgesia 
after general anaesthetic caesarean section. 
 
INVESTIGATOR: DR A.A. Bamigboye 
INSTITUTIONS: Nelspruit Medi-Clinic and the University of Witwatersrand 
DAYTIME AND AFTER HOURS TELEPHONE NUMBERS: 013 7528274; 0824647142 
This consent form may contain words that you do not understand.  Please ask me or the study staff to explain any 
words or information that you do not clearly understand.    
You are invited to consider participating in a research study.  Your participation in this study is entirely voluntary. 
This clinical study protocol has been submitted to the University of the Witwatersrand, Human Research Ethics 
Committee (HREC) and written approval has been granted by that committee.  
This information leaflet is to help you to decide if you would like to participate. You should fully understand what is 
involved before you agree to take part in this study. If you have any questions, do not hesitate to ask me. You 
should not agree to take part unless you are satisfied about all the procedures involved. If you decide to take part 
in this study, you will be asked to sign this document to confirm that you understand the study.  
PURPOSE OF THE STUDY AND PROCEDURE 
You will be delivering your baby by caesarean section soon under general anaesthesia. I would like you to 
consider taking part in the research of an injection called ropivacaine (naropin). This injection is used to deaden 
the area of skin where the operation is done (for example used by dentist to deaden the gum during tooth 
extraction to prevent or minimise pain).The purpose of this study is to determine whether, if this injection is used 
on the wound of your operation, it will reduce the amount of pain that you will experience. The study will compare 
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ropivacaine (naropin) with a placebo, an inactive injection which does not contain any medicine. You will be 
randomly allocated to one or other treatment (i.e. like spinning a coin).  Neither you nor I will know which 
treatment you are receiving during your participation in the study. This procedure helps to ensure that the 
information gathered during the study is accurate.  In case of an emergency, it will however be possible to 
determine which treatment you have been receiving. 
The study will be performed at the Medi-Clinic private Hospital on one hundred patients undergoing caesarean 
sections. Your baby will be delivered under general anaesthesia through the abdomen and handed over to the 
baby doctor (paediatrician) before we inject the wound. This procedure is routinely done by some doctors but we 
are still not certain if it works. The difference between this procedure and the one routinely done is that all the 
layers of the abdomen will be injected instead of the skin alone. 
Ropivacaine is a well tested injection for blocking pain and even though side effects have been reported when 
excessive dosages were used, it is the safest of all the local anaesthetic agents. Problems like dizziness, fits and 
vomiting may occur in patient who are awake and receive overdose or injection into the blood veins but because 
you will be sleeping under general anaesthesia, this may not show and there are effective measures to treat 
them. Less than the maximum recommended dose of Naropin will be used. After the operation, we shall be 
asking you about your pain at intervals and will give you pain injection if necessary. The potential benefit from this 
study may be less pain after your operation. However, you may not benefit from this study especially if you belong 
to the placebo (dummy) group but you will receive the usual treatment for pain control. Your participation in this 
study will contribute to medical knowledge that may help other patients to control their pain after operation. If you 
decide not to take part in this study you will still receive the best current care for your operation .Your participation 
in this study is entirely voluntary and you can decline to participate, or stop at any time, without stating any 
reason.  Your withdrawal will not affect your access to other medical care. We shall cover the costs of all study 
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procedures and reasonable medical expenses that you may incur as a direct result of this study. Neither you nor 
your medical scheme will be expected to pay for any study material or study procedures.   
 
All information obtained during the course of this study, including hospital records, personal data and research 
data will be kept strictly confidential.  Data that may be reported in scientific journals will not include any 
information that identifies you as a participant in this study. 
The 24-hour telephone number, through which you can reach me or another authorised person, is 0824647142.If 
you want any information regarding your rights as a research participant, or complaints regarding this research 
study, you may contact Prof. Cleaton-Jones, Chairperson of the University of the Witwatersrand, Human 
Research Ethics Committee (HREC), which is an independent committee established to help protect the rights of 
research participants at (011) 717 2229. 
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INFORMED CONSENT 
I hereby confirm that I have been informed by the study doctor - Dr A.A. Bamigboye about the nature, conduct, 
benefits and risks of the clinical study of Pre-emptive ropivacaine wound infiltration and peritoneal spraying for 
post operative analgesia after general anaesthetic caesarean section. I have also received, read and understood 
the above written information (Participant Information Leaflet and Informed Consent) regarding the clinical study. I 
am aware that the results of the study, including personal details regarding my sex, age, date of birth, initials and 
diagnosis will be anonymously processed into a study report. In view of the requirements of research, I agree that 
the data collected during this study can be processed in a computerized system. I may, at any stage, without 
prejudice, withdraw my consent and participation in the study .I have had sufficient opportunity to ask questions 
and (of my own free will) declare myself prepared to participate in the study.  
 
……………………………………       ……………………………………..            ………………………. 
Printed Name     Signature / Mark or Thumbprint   Date and Time 
I, Dr Bamigboye, herewith confirm that the above participant has been fully informed about the nature, conduct 
and risks of the above study. 
 
Dr A Bamigboye            …………………………                           …………………………….. 
Printed Name   Signature   Date and Time 
 
Notes or any other comment 
-------------------------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------------------------------------------------------------------------------  
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DATA COLLECTION FORM 
      
 
 
 
                                 STUDY NO… 
Age  
Weight  
Parity  
No(s) of CS  
Midline or Pfannenstiel incision  
Time skin closed in theatre  
Time in recovery room, when first pethidine was 
given, if needed 
 
Pethidine needed 1st 1 hr? YES or NO 
 
 
Total Pethidine in mg  1st  8 hours   
Time when first pethidine given in labour ward 
 
 
Total Pethidine needed post operative 
 
Additional analgesic e.g. VOLTAREN 75 mg imi  
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needed?  
RECOVERY ROOM TO COMPLETE LABOR WARD TO COMPLETE 
PAIN 15 MIN.  
**Pain score(0-10) = 
 
No pain                     mild pain 
 
Severe/unbearable 
PAIN 60 MIN 
**Pain score (0-10) = 
 
No pain                                Mild          
 
Severe/unbearable pain                          
PAIN 2HRS.                       Pain score = 
 
No pain                           Mild pain 
 
Severe/unbearable pain                        
PAIN 4HRS.                    Pain score= 
 
No pain  
                                 Mild pain 
 
Severe/unbearable pain                          
PAIN 8HRS.                         Pain score = 
 
No pain                                  Mild pain 
 
Severe/unbearable pain                          
 
PAIN 16HRS.                    Pain score = 
 
No pain                                Mild pain 
 
Severe/unbearable pain  
 
PAIN 24HRS.                       Pain score = 
 
No pain                               Mild pain 
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Severe/unbearable pain                        
No of Tramadol/acetaminophen used - 2nd 24hrs.   
Temp above 38 deg celcius-1st 24hrs Yes                          No   
Temp above 38 deg celcius-2nd 24 hrs Yes                         No       
 
Any episode of itching 
 
Yes                           No           
Total No of episodes of vomiting Yes                          No 
Septic wound. Please thick Yes                           No        
Level of satisfaction of pain control prior hospital 
discharge. Please tick 
Excellent/good 
Average 
unsatisfactory 
Level of general post delivery care satisfaction 
 
   Excellent/good  
      average       
unsatisfactory               
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ADVERSE EVENTS FORM 
 
STUDY NO:  
HOSPITAL NO/STICKER: 
DESCRIPTION OF EVENT: 
…………………………………………………………………………………………......................................................…
……………………………………………………………………………………………………………………………………
……………………………………………………………………………………………………………………………… 
Relation of event to trial medication:   
 
 
 
 
 
 
 
 
 
TREATMENT AND/ OR MANAGEMENT OF EVENT                                          
.....................................................................................................................................................................................
.................................................................................................................................................................................... 
 
 
Likely Unlikely 
Not Related Related 
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DATA COLLECTION TABLES  
 
Baseline data, expressed as mean (standard deviation) or proportions (percent). (If distribution not normal, 
median [interquartile range] will be used). 
 
 
 
 Ropivacaine Placebo 
BASELINE DATA N  N  
Age (years)     
Primiparous     
Weight     
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Outcomes expressed as mean (standard deviation) or proportions (percent) 
 
Outcomes Ropivacaine Placebo Relative 
risk/mean 
difference 
95% 
confidenc
e interval 
Primary: N  N    
Need for pethidne within 60 
min  
      
Severe/unbearable pain at 
60min 
      
Secondary outcomes N          
Mean pethidine used 1st 8hrs       
Mean pethidine used 2nd 
8hrs 
      
Mean pethidine used 3rd 
8hrs 
      
Mean pethidine used in 
24hrs 
      
Severe/unbearable pain at 2 
hrs 
      
Severe/unbearable pain at 4 
hrs. 
      
Severe/unbearable pain       
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8hrs. 
Severe/unbearable pain at 
16 hrs. 
      
Severe/unbearable pain at 
24 hrs. 
      
Mean visual analogue score 
15min 
      
Mean visual analogue score 
1hr 
      
Mean visual analogue score 
2hrs 
      
Mean visual analogue score 
4hrs 
      
Mean visual analogue score 
8hrs 
      
Mean visual analogue score 
16hrs 
      
Mean visual analogue score 
24hrs 
      
Mean dosage of pethidine 
used in 24 hours 
      
Temp >38deg C       
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Total no of 
tramadol/acetaminophen 
used 
      
Level of satisfaction-PAIN       
Level of satisfaction-
GENERAL 
      
Episodes of itching       
Episodes of vomiting       
Any other drug reaction       
Wound infection       
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PATIENT INFORMATION SHEET – PHARMACOKINETIC STUDY OF ROPIVACAINE FOLLOWING 
CAESAREAN SECTION WOUND INFILTRATION. 
 
I, Dr A.A. Bamigboye of the Medi-Clinic Hospital and the University of the Witwatersrand, is conducting a study to 
see whether an injection called ropivacaine, in addition to the normal treatment, reduces the pain that women 
experience on waking up in theatre after the birth of their babies by Caesarean section.  
You are kindly invited to participate in the study. If you accept this invitation, the injection will be given at the site 
of the operation to deaden some nerves in the abdomen after your baby has been delivered. This injection works 
for about 4-8 hours which is the time of maximum pain after the operation. Some doctors believe the injection 
reduces pain after the operation. Other doctors believe it does not. 100 women have already participated in this 
study to show whether the medication reduces pain or not. We are still awaiting the result for these women.  
Even though 100 women already had this injection in this research and thousands all over the world had used this 
injection following Caesarean section, we are yet to measure the amount of this medicine in women who 
delivered their babies by operation and used this injection to reduce pain. The dose of the injection we shall use is 
within the recommended level that has been used in adults.  We need 10 women to take blood from and measure 
the amount of the injection - ropivacaine - in blood at different times. 
To measure the amount of the injection in your blood, while you are sleeping during the operation, the sleep 
doctor (anaesthetist) will insert a very small baby plastic needle through which blood will be taken at different 
times. A teaspoonful (5mls) of blood will be taken from you in 15 minutes, 30 minutes, 60 minutes, 2 hours, 4 
hours, 8 hours 16 hours and 24 hours after the operation. The total amount of blood taken will be less than a third 
of a glass of wine. If this amount of blood is removed in an adult, it does not have any short or long term effect. 
The bloods will thereafter be sent for laboratory analysis. 
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There may be benefits to participating in this study. The injection that we are studying may decrease the amount 
of pain that you will experience after the operation.  By participating you will be helping to ensure that women, in 
future, get the best treatment for pain control after Caesarean section. This injection (ropivacaine) is not new and 
has been well used for many years. The few side effects including allergies are known but rare and treatment of 
such is available. There is also a possibility of discomfort because of the needle that will be left in your arm for 24 
hours and the injection needle site may swell up and rarely be infected. Should you have any of these complains 
we shall act appropriately to correct and treat them.  
 
Any information you provide during the study will be kept confidential.  Your name will not appear on any study 
document and only staff participating in the study will have access to the information you provide.  You are free to 
choose whether or not you wish to participate.  You are also free to withdraw from the study at any time should 
you wish to do so for any reason.  If for any reason you are not eligible for the study, or decide not to participate, 
you will still receive normal care and standard treatment and medications before, during and after birth.  We hope 
you will participate and thank you if you do. 
Do you have any questions about the study? 
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CONSENT  
Taking blood for measurement after ropivacaine injection to Caesarean section wound to relieve pain 
I have read (or been read to) the information sheet concerning this study and I understand the content of the 
research.  All my questions and doubts have been answered.  I understand that I can withdraw from the study at 
any time I wish without giving a reason and this will not affect the normal health care I receive. 
I would like/ would not like to be informed about the results of the trial (circle or cross) 
I… … … … … … … … … … … … … ………………. (Participant‘s full name) agree to take part in this study.   
signature…………………………………………………..…..Date…………………………………….……. 
 
Consenting doctor‘s name ………………………………………………………………..…. 
 
Signature……………………………………………………………………Date…………………………… 
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     PHARMACOKINETIC STUDY RECORD SHEET 
 
 
Study No…………………………. 
 
 
Patients Sticker 
 
 
 
 
 
 
Age………………Weight………………….Height………………Parity……………. 
 
 
Time of Ropivacaine injection--------------------------------------- 
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Sample time (min) Time  Signature phlebotomist 
Before injection 
 
  
15min 
 
  
30min 
 
  
60min 
 
  
2hrs 
 
  
4hrs 
 
  
8hrs 
 
  
16hrs 
 
  
24hrs 
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APPENDIX 2. 
 
 
Study identifier: Bamigboye 2008 
Review: Local anesthetic wound infiltration and abdominal nerves block during caesarean section for postoperative pain 
relief 
Reviewer: Tess Lawrie  
Date: 16 February 2011 
Summary: 
Methods: RCT conducted in Nelspruit, South Africa. Randomisation by computer-generated list. Allocation concealed in 
sealed, opaque envelopes. Theatre manager prepared solution. Theatre staff, surgeon and pain assessors were blind to 
group allocation.  
Participants: 100 women undergoing elective CS (50 in each group). Excluded if they did not consent, history of local 
anesthetic reactions, hypertension in pregnancy with proteinuria, cardiac diseases and any other major medical disorder 
associated with pregnancy. 
Interventions: 30 mls 7.5mg/ml solution ropivacaine or 30 mls normal saline (10 mls sprayed onto divided ages of the 
peritoneum, 10 mls injected into the edges of the rectus aponeurosis and 10 mls injected subcut along wound edges).Post-
op 100mg pethidine every 3-4 hours and 75mg diclofenac every 12 hours were administered as necessary. 
Outcomes: Pain assessed by a visual analogue scale at 15 min, 1, 2, 4, 8, 16, and 24 hours post op (dichotomous and 
continuous variables); pethidine at 1 hour, 8 hours and 24 hours post-op (mean [SD])  
In the LA group = significant reduction in severe pain was reported at 15 min and 2 hours post op and significantly less 
pethidine used at 1 hour post-op. 
Notes: Standardised method of general anesthetic and surgical incisions used (pfannenstiel in all but 2 cases). Baseline 
characteristics were similar. 
Decision: A well-designed study that fulfils the inclusion criteria for the above review. 
 
 
Dr TA Lawrie (MBBCH, PhD, DFSRH) 
Systematic reviewer for Cochrane Review Groups 
tess@lawrie.com 
+44 1225 428021 
+44 7826 939464 
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Assessment of risk of bias: 
 (1) Sequence generation (checking for possible selection bias) 
 adequate (e.g. random number table; computer random number generator; tossing a coin, minimisation); 
 inadequate (odd or even date of birth; hospital or clinic record number); 
 unclear.    
 (2) Allocation concealment (checking for possible selection bias) 
 adequate (e.g. telephone or central randomisation; consecutively numbered sealed opaque envelopes); 
 inadequate (open random allocation; unsealed or non-opaque envelopes; alternation; date of birth); 
 unclear.    
(3) Blinding (checking for possible performance bias) 
 adequate, inadequate or unclear for participants; 
 adequate, inadequate or unclear for personnel; 
 adequate, inadequate or unclear for outcome assessors. 
(4) Incomplete outcome data (checking for possible attrition bias through withdrawals, dropouts, protocol deviations) 
 adequate (e.g. where there was no missing data or low levels of missing data (less than 20%) and where reasons 
for missing data are balanced across groups); 
 inadequate (e.g. where missing data are likely to be related to outcomes or are not balanced across groups); 
 unclear (e.g. where there is insufficient reporting of attrition or exclusions to permit a judgment to be made). 
(5) Selective reporting bias 
 adequate (where it is clear that all of the study‘s prespecified outcomes and all expected outcomes of interest to 
the review have been reported); 
 inadequate (where not all of the study‘s prespecified outcomes have been reported; one or more reported primary 
outcomes were not prespecified; outcomes of interest are reported incompletely and so cannot be used; study fails 
to include results of a key outcome that would have been expected to have been reported); 
 unclear. 
(6) Other sources of bias (For example, if there was extreme baseline imbalance or any other problems that may have had 
an effect on outcomes) 
 yes; 
 no; 
 unclear. 
(7) Overall risk of bias (the likely magnitude and direction of the bias and whether we consider it is likely to impact on the 
findings) low risk of bias 
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APPENDIX 3.  
 
SOME LETTERS AND CERTIFICATES OF AWARD 
 
Dear Dr Bamigboye, 
 
I thought you would be pleased to know that one of your articles [Local anesthetic wound infiltration and 
abdominal nerves block during caesarean section for postoperative pain relief., Cochrane Database Syst Rev, 
2009] has been selected for Faculty of 1000 Medicine (www.f1000medicine.com) and evaluated by Frederic 
Mercier see http://www.f1000medicine.com/article/25x4wylm7zkrng4/id/1165629 - Congratulations! 
 
Faculty of 1000 Medicine (www.f1000medicine.com) is a revolutionary literature awareness service that identifies 
and evaluates the most important articles published in Medicine based on the recommendations of a Faculty of 
over 2000 peer-nominated leading researchers and clinicians. Your article's identification and inclusion provides 
recognition from your peers of its scientific merit and the positive contribution it makes to the medical literature. 
 
Many of the world's leading medical institutions already subscribe to Faculty of 1000 Medicine. If your institution 
does not yet subscribe, you can recommend the service to your librarian using our online form 
http://www.f1000medicine.com/freetrial/recommendation. 
 
To find out more about Faculty of 1000 Medicine, visit our About Pages at www.f1000medicine.com/about. You 
can also customize the service to receive tailored e-mail alerts consisting of the articles most relevant to your 
research interests: just register to use "My F1000" (www.f1000medicine.com/my/) and then select your areas of 
interest and email preferences. 
 
Finally, don't forget to check out our Hidden Jewels (www.f1000medicine.com/top10/jewels/) 
 
Many congratulations again on your success! 
 
Kind regards, 
Anne Greenwood 
Managing Director, Faculty of 1000 
 
******* 
Faculty of 1000 Medicine 
Medicine Reports Ltd, Middlesex House, 34-42 Cleveland Street, London W1T 4LB, UK editorial@f1000.com; 
www.f1000medicine.com 
******* 
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Managing Editor 
Clare Last  
Tel: +44 (0) 207 928 1166 
Fax: +44 (0) 207 928 7099 
E-mail: ijgo@figo.org 
 
 
 
8 May 2009 
 
 
Dear Dr Bamigboye 
 
On behalf of the editors of the International Journal of Gynecology and Obstetrics (IJGO) and the Executive Board 
of the International Federation of Gynecology and Obstetrics (FIGO), we are pleased to notify you and your co-
authors that your article, "Ropivacaine abdominal wound infiltration and peritoneal spraying at Caesarean delivery 
for pre-emptive analgesia‖ has received an Honorable Mention in the John J. Sciarra IJGO Prize Paper Award for 
2008.  Although the Honorable Mention recognition does not include a financial reward, you and you co-authors 
will each receive a certificate, which we hope you will be proud to display.  As corresponding author, you will be 
sent the certificates and we ask that you distribute them among your co-authors. Please send your contact 
address details to Clare Last (Clare@figo.org) at the earliest opportunity. 
 
All clinical research articles from low-income countries that were published during 2008 were considered for this 
prize.  Selection was made by the editors and was endorsed by the IJGO editorial board. 
 
This award was established in 1998 for the purpose of encouraging investigators from low-income countries to 
submit their best clinical research articles for publication in the IJGO. 
 
The editors of the IJGO and the Executive Board of FIGO extend our congratulations to you and your co-authors 
on the receipt of this Honourable Mention recognition. 
 
Sincerely, 
 
 
 
 
Timothy R.B. Johnson, MD. Editor 
International Journal of 
Gynaecology  
& Obstetrics 
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EXCERPTS FROM SOME OF THE INTERVIEWS GRANTED AND PUBLISHED.  Assessed on google engine 
search on 21-03-2010. 
Local anaesthetic during C-section curbs later pain 
• Gynaecology news • Jul 27, 09 
Two pain-relieving techniques done during Caesarean section may reduce women‘s need for 
narcotic painkillers afterward, a research review finds.  
After having a C-section, women are typically given a combination of painkillers, including opiate 
drugs such as morphine. But opioids come with side effects like forgetfulness and sedation, and can be transferred to breast milk, leading to drowsiness in the 
infant.  
The new review, of 20 clinical trials, found that adding either of two interventions to standard anaesthesia during C-section reduced women‘s pain and need for 
opiates after giving birth.  
One intervention is known as an abdominal nerve block, in which a nerve- dulling drug is injected into the 
abdomen before the C-section incision is made. The other is called wound infiltration, in which a surgeon 
irrigates the surgical wound with a solution containing painkillers such as ibuprofen.  
Based on the review findings, women planning on having a C-section can ask their doctors about having either option, lead researcher Dr. Anthony A. 
Bamigboye, of the University of Witwatersrand in South Africa, told Reuters Health.  
The findings are published in the Cochrane Database of Systematic Reviews, part of the Cochrane Library.  
The time immediately after birth is an important period of mother- infant bonding, Bamigboye explained, so new mothers should ideally have the least amount of 
pain possible and be able to start breastfeeding right away.  
―Any intervention that can make this goal a reality cannot be overstated,‖ Bamigboye said.  
None of the trials in the review tested whether abdominal nerve block or wound infiltration affected women‘s risk of chronic pelvic pain in the long term. Future 
studies should look at that question, as well as the costs of local anesthetics, the researchers say.  
 
http://www.bupa.co.uk/individuals/health-information/health-news-index/hi-090709-caesarean-local-
anaesthetic 
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Local anaesthetic during a caesarean reduces need for painkillers  
10 July 2009 
‗The period immediately after delivery is a significant milestone in the reproductive life of a new mother, and any 
measure to reduce the unpleasant experience of pain cannot be underestimated‘ 
 Dr Anthony Bamigboye, University of Witwatersrand, lead scientist  
Having a local anaesthetic during a caesarean, in addition to general or regional anaesthesia, helps manage pain 
and can reduce how many painkillers you need after the operation, according to a new Cochrane review. 
The review, carried out by scientists at the University of Witwatersrand in South Africa, combined the results of 20 
studies into the effects of local anaesthetic on pain relief after a caesarean. Altogether, the studies looked at 
1,150 women who gave birth by caesarean delivery. 
Caesareans are done under regional or general anaesthesia. General anaesthesia means that you will be asleep 
during the operation. Regional anaesthetic completely blocks feeling from your waist down, but you will stay 
awake during the operation. 
A local anaesthetic can be used during a caesarean, in addition to regional or general anaesthesia. It can be 
injected into your abdominal (tummy) wall before your skin is cut or after the cut is closed at the end of the 
operation (abdominal nerve block), or it can be applied directly to the wound (wound infiltration). 
The review found that women having a caesarean under regional anaesthesia with local anaesthetic wound 
infiltration or abdominal nerve block needed fewer painkillers after the operation. 
Women having a general anaesthetic and wound infiltration with local anaesthetic needed fewer painkillers during 
the first 24 hours after the operation. Those who had general anaesthesia and abdominal nerve block had less 
pain within the first 24 hours. 
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The scientists concluded that local anaesthesia infiltration or abdominal nerve block, in addition to regional or 
general anaesthesia, helps to reduce pain after a caesarean. 
"It is inevitable to advise physicians performing caesarean sections to use local anaesthetics in addition to pain 
relief." Dr Anthony Bamigboye, lead author of the review, told the Bupa health information team. 
"The period immediately after delivery is a significant milestone in the reproductive life of a new mother, and any 
measure to reduce the unpleasant experience of pain cannot be underestimated." he said. 
Improvements in pain relief can make the time after a caesarean less uncomfortable, allowing mothers to start 
breastfeeding and bonding with their baby as soon as possible. 
Key facts  
 A caesarean delivery is an operation to deliver your baby through your abdomen (tummy).  
 You may need to have an emergency caesarean delivery or you may plan to give birth this way, for 
example because you have had previous abdominal surgery.  
 Child birth by caesarean delivery is becoming more common. In the UK, about one in five babies are 
delivered by caesarean.  
 If you have a caesarean delivery, you will be given an anaesthetic. You may have a general anaesthetic 
or a regional anaesthetic. Regional anaesthetics include spinal, spinal epidural or epidural block.  
 Pain after a caesarean is controlled with a combination of drugs such as morphine and other pain killers.  
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Caesarean section: Local anaesthetic reduces need for painkillers post-op 
July 7, 2009  
Giving a local anesthetic during a Caesarean section helps manage pain after the operation and can 
reduce consumption of painkillers, according to Cochrane Researchers. The researchers recommend 
local anesthetics as part of integrated pain management strategies for Caesarean section operations, 
provided that consideration is given to the cost.  
"This review is particularly important in light of the growing number of women giving birth by Caesarean section," 
says lead researcher, Anthony Bamigboye, of the Department of Obstetrics and Gynaecology at the University of 
Witwatersrand in Johannesburg, South Africa. "Improved pain relief allows mothers to bond with their babies and 
begin breastfeeding more quickly."  
Caesarean sections account for around a quarter of all births in the US, Canada and the UK. Local anaesthetics 
can be given, in addition to general or regional anaesthetics, to help manage pain during and after operations. 
The anaesthetic is either injected to block nerves in the abdominal wall or applied directly to the wound as an 
anaesthetic solution.  
The researchers reviewed data from 20 studies that together involved 1,150 women who gave birth by Caesarean 
section in both developing and developed countries. They found that women treated with local anaesthetic as well 
as local or regional anaesthesia did not require as much morphine or other opioid drugs for pain relief after their 
operations. When non-steroidal anti-inflammatory drugs were also given, pain was reduced further.  
One concern, however, is the additional cost of giving local anaesthetic. "None of the trials in this review 
addressed the cost implications of increasing use of local anaesthetic," says Bamigboye. "A cost benefit analysis 
is needed to find out whether increased expenditure on theatre time and local anaesthetic can be offset by 
reductions in postoperative painkillers."  
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